dmtp20210331

0001437749-21-010912.txt : 20210505 0001437749-21-010912.hdr.sgml : 20210505 20210505163220 ACCESSION NUMBER: 0001437749-21-010912 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20210331 FILED AS OF DATE: 20210505 DATE AS OF CHANGE: 20210505 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DiaMedica Therapeutics Inc. CENTRAL INDEX KEY: 0001401040 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: Z4 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36291 FILM NUMBER: 21893911 BUSINESS ADDRESS: STREET 1: 2 CARLSON PARKWAY STREET 2: SUITE 260 CITY: MINNEAPOLIS STATE: MN ZIP: 55447 BUSINESS PHONE: (763) 496-5454 MAIL ADDRESS: STREET 1: 2 CARLSON PARKWAY STREET 2: SUITE 260 CITY: MINNEAPOLIS STATE: MN ZIP: 55447 FORMER COMPANY: FORMER CONFORMED NAME: DiaMedica Inc. DATE OF NAME CHANGE: 20070525 10-Q 1 dmtp20210331_10q.htm FORM 10-Q dmtp20210331_10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark one)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934‐‐

For the transition period from ________________ to __________________.

Commission File Number: 001-36291

DIAMEDICA THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

British Columbia

(State or other jurisdiction of incorporation or organization)

Not Applicable

(I.R.S. Employer Identification No.)

Two Carlson Parkway, Suite 260

Minneapolis, Minnesota 55447

(Address of principal executive offices) (Zip code)

(763) 312-6755

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Voting common shares, no par value per share	DMAC	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

Non-accelerated filer ☒

Smaller reporting company ☒

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

As of May 3, 2021, there were 18,786,157 voting common shares of the registrant outstanding.

DiaMedica Therapeutics Inc.

FORM 10-Q

March 31, 2021

TABLE OF CONTENTS

Description		Page

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS		1

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements	2
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	19
Item 4.	Controls and Procedures	19

PART II.	OTHER INFORMATION
Item 1.	Legal Proceedings	20
Item 1A.	Risk Factors	20
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	20
Item 3.	Defaults Upon Senior Securities	20
Item 4.	Mine Safety Disclosures	21
Item 5.	Other Information	21
Item 6.	Exhibits	21

SIGNATURE PAGE		22

This quarterly report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the United States Securities Act of 1933, as amended, and Section 21E of the United States Securities Exchange Act of 1934, as amended, that are subject to the safe harbor created by those sections. For more information, see “Cautionary Note Regarding Forward-Looking Statements.”

As used in this report, references to “DiaMedica,” the “Company,” “we,” “our” or “us,” unless the context otherwise requires, refer to DiaMedica Therapeutics Inc. and its subsidiaries, all of which are consolidated in DiaMedica’s condensed consolidated financial statements. References in this report to “common shares” mean our voting common shares, no par value per share.

We own various unregistered trademarks and service marks, including our corporate logo. Solely for convenience, the trademarks and trade names in this report are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the owner of such trademarks and trade names will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies’ trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Statements in this report that are not descriptions of historical facts are forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 that are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and share price. We have attempted to identify forward-looking statements by terminology including “anticipates,” “believes,” “can,” “continue,” “could,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “should,” “will,” “would,” the negative of these terms or other comparable terminology, and the use of future dates.

The forward-looking statements in this report include, among other things, statements about:

●

our plans to develop, obtain regulatory approval for and commercialize our DM199 product candidate for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD) and our expectations regarding the benefits of our DM199 product candidate;

●

our ability to conduct successful clinical testing of our DM199 product candidate for AIS and CKD and certain anticipated dates with respect to our pending and anticipated clinical trials;

●

our ability to obtain required regulatory approvals of our DM199 product candidate for AIS and CKD;

●

the perceived benefits of our DM199 product candidate over existing treatment options for AIS and CKD;

●

the potential size of the markets for our DM199 product candidate and our ability to serve those markets;

●

the rate and degree of market acceptance, both in the United States and internationally, of our DM199 product candidate for AIS and CKD;

●

our ability to partner with and generate revenue from biopharmaceutical or pharmaceutical partners to develop, obtain regulatory approval for and commercialize our DM199 product candidate for AIS and CKD;

●

the success, cost and timing of planned clinical trials, as well as our reliance on collaboration with third parties to conduct our clinical trials;

●

our expectations regarding the impact of the novel strain of coronavirus, or COVID-19, pandemic on our business, including in particular the conduct of our clinical trials and the timing thereof;

●

our commercialization, marketing and manufacturing capabilities and strategy;

●

expectations regarding federal, state, and foreign regulatory requirements and developments, such as potential United States Food and Drug Administration (FDA) regulation of our DM199 product candidate for AIS and CKD;

●

expectations regarding competition and our ability to obtain data exclusivity for our DM199 product candidate for AIS and CKD;

●

our ability to obtain funding for our operations, including funding necessary to complete planned clinical trials and obtain regulatory approvals for our DM199 product candidate for AIS and CKD;

●

our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;

●

our expectations regarding our ability to obtain and maintain intellectual property protection for our DM199 product candidate; and

●

our anticipated use of the net proceeds from our underwritten public offerings.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described under “Part I. Item 1A. Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2020 and those described above and elsewhere in this report. Moreover, we operate in a very competitive and rapidly-changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Except as required by law, including the securities laws of the United States, we do not intend to update any forward-looking statements to conform these statements to actual results or to changes in our expectations.

PART I - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

DiaMedica Therapeutics Inc.

Condensed Consolidated Balance Sheets

(In thousands, except share amounts)

	March 31, 2021			December 31, 2020
	(unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$	3,329		$	7,409
Marketable securities		20,072			20,098
Amounts receivable		337			340
Prepaid expenses and other assets		457			74
Total current assets		24,195			27,921

Non-current assets:
Operating lease right-of-use asset		86			100
Property and equipment, net		75			74
Total non-current assets		161			174

Total assets	$	24,356		$	28,095

LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	689		$	1,099
Accrued liabilities		420			864
Finance lease obligation		6			6
Operating lease obligation		63			59
Total current liabilities		1,178			2,028

Non-current liabilities:
Finance lease obligation, non-current		5			7
Operating lease obligation, non-current		28			46
Total non-current liabilities		33			53

Shareholders’ equity:
Common shares, no par value; unlimited authorized; 18,786,157 and 18,746,157 shares issued and outstanding, as of March 31, 2021 and December 31, 2020, respectively		—			—
Paid-in capital		95,680			94,925
Accumulated other comprehensive loss		(4	)		(2	)
Accumulated deficit		(72,531	)		(68,909	)
Total shareholders’ equity		23,145			26,014
Total liabilities and shareholders’ equity	$	24,356		$	28,095

See accompanying notes to the condensed consolidated financial statements.

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

(Unaudited)

	Three Months Ended March 31,
	2021			2020
Operating expenses:
Research and development	$	2,406		$	1,349
General and administrative		1,213			1,055
Operating loss		(3,619	)		(2,404	)

Other (income) expense:
Governmental assistance - research incentives		—			(115	)
Other (income) expense, net		(4	)		127
Total other (income) expense		(4	)		12

Loss before income tax expense		(3,615	)		(2,416	)

Income tax expense		7			9

Net loss		(3,622	)		(2,425	)

Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities		(2	)		40

Net loss and comprehensive loss	$	(3,624	)	$	(2,385	)

Basic and diluted net loss per share	$	(0.19	)	$	(0.19	)
Weighted average shares outstanding – basic and diluted		18,766,656			13,107,725

See accompanying notes to the condensed consolidated financial statements.

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Shareholders’ Equity

For the Three Months Ended March 31, 2021 and 2020

(In thousands, except share and per share amounts)

(Unaudited)

	Common Shares		Paid-In Capital		Accumulated Other Comprehensive Income			Accumulated Deficit			Total Shareholders’ Equity
Balances at December 31, 2020		18,746,157	$	94,925	$	(2	)	$	(68,909	)	$	26,014
Exercise of common stock options		40,000		244		—			—			244
Share-based compensation expense		—		511		—			—			511
Unrealized loss on marketable securities		—		—		(2	)		—			(2	)
Net loss		—		—		—			(3,622	)		(3,622	)
Balances at March 31, 2021		18,786,157	$	95,680	$	(4	)	$	(72,531	)	$	23,145

	Common Shares		Paid-In Capital		Accumulated Other Comprehensive Income		Accumulated Deficit			Total Shareholders’ Equity
Balances at December 31, 2019		12,006,874	$	64,232	$	2	$	(56,617	)	$	7,617
Issuance of common shares net of offering costs of $819		2,125,000		7,682		—		—			7,682
Exercise of common stock options		7,200		16		—		—			16
Share-based compensation expense		—		393		—		—			393
Unrealized gain on marketable securities		—		—		40		—			40
Net loss		—		—		—		(2,425	)		(2,425	)
Balances at March 31, 2020		14,139,074	$	73,323	$	42	$	(59,042	)	$	13,323

See accompanying notes to the condensed consolidated financial statements.

DiaMedica Therapeutics Inc.

Condensed Consolidated Statements of Cash Flows

(In thousands)

(Unaudited)

	Three Months Ended March 31,
	2021			2020
Cash flows from operating activities:
Net loss	$	(3,622	)	$	(2,425	)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation		511			393
Amortization of discount on marketable securities		26			(14	)
Non-cash lease expense		14			13
Depreciation		6			6
Changes in operating assets and liabilities:
Amounts receivable		3			(162	)
Prepaid expenses and other assets		(383	)		(397	)
Accounts payable		(410	)		262
Accrued liabilities		(458	)		(654	)
Net cash used in operating activities		(4,313	)		(2,978	)

Cash flows from investing activities:
Purchase of marketable securities		(11,923	)		(8,799	)
Maturities of marketable securities		11,921			3,500
Purchases of property and equipment		(9	)		(2	)
Proceeds from disposition of property and equipment		2			—
Net cash used in investing activities		(9	)		(5,301	)

Cash flows from financing activities:
Proceeds from issuance of common shares, net of offering costs		—			7,682
Proceeds from the exercise of stock options		244			16
Principal payments on finance lease obligations		(2	)		(2	)
Net cash provided by financing activities		242			7,696

Net decrease in cash and cash equivalents		(4,080	)		(583	)
Cash and cash equivalents at beginning of period		7,409			3,883
Cash and cash equivalents at end of period	$	3,329		$	3,300

See accompanying notes to the condensed consolidated financial statements.

DiaMedica Therapeutics Inc.
Notes to the Condensed Consolidated Financial Statements

(Unaudited)

1.	Business

DiaMedica Therapeutics Inc. and its wholly-owned subsidiaries, DiaMedica USA, Inc. and DiaMedica Australia Pty Ltd. (collectively we, us, our, DiaMedica and the Company), are focused on developing novel treatments for neurological disorders and kidney diseases. Currently, our primary focus is on developing DM 199, a proprietary recombinant human tissue kallikrein-1 (KLK1) protein for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Our parent company is governed under the British Columbia Business Corporations Act, and our common shares are publicly traded on The Nasdaq Capital Market under the symbol “DMAC.”

2.	Risks and Uncertainties

DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union and comparable agencies in other countries. We are in the clinical stage of development of our initial product candidate, DM199, for the treatment of AIS and CKD. The Company has not completed the development of any product candidate and, accordingly, has not begun to commercialize any product candidate or generate any revenues from the commercial sale of any product candidate. DM199 requires significant additional clinical testing and investment prior to seeking marketing approval and is not expected to be commercially available for at least three to five years, if at all. The Company’s future success is dependent upon the success of its development efforts, its ability to demonstrate clinical progress for its DM199 product candidate in the United States or other markets, its ability to obtain required governmental approvals of its product candidate, its ability to license or market and sell its DM199 product candidate and its ability to obtain additional financing to fund these efforts.

As of March 31, 2021, we have incurred losses of $72.5 million since our inception in 2000. For the three months ended March 31, 2021, we incurred a net loss of $3.6 million and negative cash flows from operating activities of $4.3 million. We expect to continue to incur operating losses until such time as any future product sales, royalty payments, licensing fees, and/or milestone payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical trials of, and to seek regulatory approval for, our DM199 product candidate. As of March 31, 2021, DiaMedica had cash and cash equivalents of $3.3 million, marketable securities of $20.1 million, working capital of $23.0 million and shareholders’ equity of $23.1 million. Our principal source of cash has been net proceeds from the issuance of equity securities. Although the Company has previously been successful in obtaining financing through equity securities offerings, there is no assurance that we will be able to do so in the future. This is particularly true if our clinical data is not positive or economic and market conditions deteriorate.

We expect that we will need substantial additional capital to further our research and development activities, complete the required clinical trials and regulatory activities and otherwise develop our product candidate, DM199, or any future product candidates, to a point where they may be commercially sold. We expect our current cash, cash equivalents and marketable securities, to be sufficient to allow us to complete our currently ongoing Phase 2 study in patients with CKD and to otherwise fund our planned operations for at least the next twelve months from the date of issuance of these financial statements. However, the amount and timing of our future funding requirements will depend on many factors, including the timing and results of ongoing development efforts, the potential expansion of current development programs, potential new development programs and related general and administrative support. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.

3.	Summary of Significant Accounting Policies

Interim financial statements

We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10-Q and Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations, consolidated statement of shareholders’ equity and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2020 was derived from our audited consolidated financial statements. Certain prior year amounts have been reclassified to conform to the current year presentation. These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.

Cash and cash equivalents

The Company considers all bank deposits, including money market funds, and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.

Concentration of credit risk

Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with one financial institution. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.

Marketable securities

The Company’s marketable securities typically consist of obligations of the United States government and its agencies, investment grade corporate obligations and bank certificates of deposit, which are classified as available-for-sale and included in current assets as they are intended to fund current operations. Securities are valued based on market prices for similar assets using third party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of shareholders’ equity in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method and are included in other income in the condensed consolidated statements of operations.

Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of shareholders’ equity in accumulated other comprehensive income (loss). There were no other-than-temporary unrealized losses as of March 31, 2021.

Fair value measurements

Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The hierarchy is broken down into three levels defined as follows:

Level 1 Inputs — quoted prices in active markets for identical assets and liabilities

Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities

Level 3 Inputs — unobservable inputs

As of March 31, 2021, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled “Marketable Securities” for additional information.

Patent costs

Costs associated with applying for, prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, the resulting probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in general and administrative costs and were $48,000 and $32,000 for the three months ended March 31, 2021 and 2020, respectively.

4.	Marketable Securities

The available-for-sale marketable securities are primarily comprised of investments in commercial paper, corporate bonds and government securities and consist of the following, measured at fair value on a recurring basis (in thousands):

	Fair Value Measurements Using Inputs Considered as of:
	March 31, 2021								December 31, 2020
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Government securities	$	6,004	$	—	$	6,004	$	—	$	8,924	$	—	$	8,924	$	—
Bank certificates of deposit		245		—		245		—		496		—		496		—
Commercial paper and corporate bonds		13,823		—		13,823		—		10,678		—		10,678		—
Total	$	20,072	$	—	$	20,072	$	—	$	20,098	$	—	$	20,098	$	—

Accrued interest receivable on available-for-sale securities is included in amounts receivable and was $37,000 and $34,000 as of March 31, 2021 and December 31, 2020, respectively.

There were no transfers of assets between Level 1 and Level 2 of the fair value measurement hierarchy during the three months ended March 31, 2021.

Under the terms of the Company’s investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations and bank certificates of deposit with a primary objective of principal preservation. Maturities of individual securities are less than one year and the amortized cost of all securities approximated fair value as of March 31, 2021 and December 31, 2020.

5.	Amounts Receivable

Amounts receivable consisted of the following (in thousands):

	March 31, 2021		December 31, 2020
Research and development incentives	$	289	$	289
Sales-based taxes receivable		4		2
Other		44		49
Total amounts receivable	$	337	$	340

6.	Property and Equipment

Property and equipment consisted of the following (in thousands):

	March 31, 2021			December 31, 2020
Furniture and equipment	$	61		$	69
Computer equipment		62			62
		123			131
Less accumulated depreciation		(48	)		(57	)
Property and equipment, net	$	75		$	74

7.	Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2021		December 31, 2020
Accrued clinical study costs	$	237	$	13
Accrued research and other professional fees		143		360
Accrued compensation		33		483
Accrued taxes and other liabilities		7		8
Total accrued liabilities	$	420	$	864

8.	Operating Lease

We lease certain office space under a non-cancelable operating lease. This lease does not have significant rent escalation holidays, concessions, leasehold improvement incentives or other build-out clauses. Further this lease does not contain contingent rent provisions. This lease terminates on August 31, 2022 and we do not have an option to renew. This lease does include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset.

This lease does not provide an implicit rate and, due to the lack of a commercially salable product, we are generally considered unable to obtain commercial credit. Therefore, we estimated our incremental borrowing rate to be 9%, considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. We used our estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.

Our operating lease cost and variable lease costs were $17,000 and $14,000, respectively, for the three months ended March 31, 2021. Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.

Maturities of our operating lease obligation are as follows as of March 31, 2021 (in thousands):

2021		51
2022		46
Total lease payments	$	97
Less interest portion		(6	)
Present value of lease obligation	$	91

9.	Shareholders’ Equity

Authorized capital stock

The Company has authorized share capital of an unlimited number of voting common shares and the shares do not have a stated par value.

Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to one vote per share at the Company's annual general meeting and any special meeting.

Equity issued during the three months ended March 31, 2021

During the three months ended March 31, 2021, 40,000 common shares were issued on the exercise of options for gross proceeds of $244,000 and no warrants were exercised.

Equity issued during the three months ended March 31, 2020

On February 13, 2020, we issued and sold an aggregate of 2,125,000 common shares in a public, underwritten offering at a public offering price of $4.00 per share. As a result of the offering, we received gross proceeds of $8.5 million, which resulted in net proceeds to us of approximately $7.7 million, after deducting the underwriting discount and offering expenses.

During the three months ended March 31, 2020, 7,200 common shares were issued on the exercise of options for gross proceeds of $16,000 and no warrants were exercised.

Shares reserved

Common shares reserved for future issuance are as follows:

	March 31, 2021
Stock options outstanding		1,421,094
Deferred share units outstanding		72,142
Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan		1,050,026
Common shares issuable under common share purchase warrants		265,000
Total		2,808,262

10.

Net Loss Per Share

We compute net loss per share by dividing our net loss (the numerator) by the weighted-average number of common shares outstanding (the denominator) during the period. Shares issued during the period and shares reacquired during the period, if any, are weighted for the portion of the period that they were outstanding. The computation of diluted earnings per share, or EPS, is similar to the computation of basic EPS except that the denominator is increased to include the number of additional common shares that would have been outstanding if the dilutive potential common shares had been issued. Our diluted EPS is the same as basic EPS due to common equivalent shares being excluded from the calculation, as their effect is anti-dilutive.

The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):

	Three Months Ended March 31,
	2021			2020
Net loss	$	(3,622	)	$	(2,425	)
Weighted average shares outstanding—basic and diluted		18,766,656			13,107,725
Basic and diluted net loss per share	$	(0.19	)	$	(0.19	)

The following outstanding potential common shares were not included in the diluted net loss per share calculations as their effects were not dilutive:

	Three Months Ended March 31,
	2021		2020
Employee and non-employee stock options		1,421,094		1,181,309
Common shares issuable under common share purchase warrants		265,000		255,000
Common shares issuable under deferred unit awards		72,142		21,183

11.

Share-Based Compensation

2019 Omnibus Incentive Plan

The DiaMedica Therapeutics Inc. 2019 Omnibus Incentive Plan (2019 Plan) was adopted by the Board of Directors in March 2019 and approved by our shareholders at our annual general and special meeting of shareholders held on May 22, 2019. The 2019 Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company’s eligible employees, non-employee directors and consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards and other stock-based awards. We grant options to purchase common shares under the 2019 Plan at no less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of ten years and generally vest in approximately equal quarterly installments over one to three years. Options granted to non-employees have a maximum term of five years and generally vest in approximately equal quarterly installments over one year. Subject to adjustment as provided in the 2019 Plan, the maximum number of the Company’s common shares authorized for issuance under the 2019 Plan is 2,000,000 shares. As of March 31, 2021, options to purchase 930,684 common shares were outstanding and 50,959 common shares were reserved for issuance upon settlement of deferred share units (DSUs) under the 2019 Plan.

Prior stock option plan

The DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated November 6, 2018 (Prior Plan), was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the 2019 Plan. As of March 31, 2021, options to purchase 490,410 common shares were outstanding under the Prior Plan.

As the TSX Venture Exchange was the principal trading market for the Company’s common shares, all options granted prior to December 31, 2018 were priced in Canadian dollars. Options granted after December 31, 2018 have been priced in United States dollars.

Prior deferred share unit plan

The DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan (DSU Plan) was terminated by the Board of Directors in conjunction with the shareholder approval of the 2019 Plan. Awards outstanding under the DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of March 31, 2021, there were 21,183 common shares reserved for DSUs outstanding.

The aggregate number of common shares reserved for issuance for awards granted under the 2019 Plan, the Prior Plan and the DSU Plan as of March 31, 2021 was 1,493,234.

Share-based compensation expense for each of the periods presented is as follows (in thousands):

	Three Months Ended March 31
	2021		2020
Research and development	$	131	$	107
General and administrative		380		286
Total share-based compensation	$	511	$	393

We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.

A summary of option activity is as follows (in thousands except share and per share amounts):

	Shares Underlying Options Outstanding			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balances at December 31, 2020		1,389,568		$	5.38	$	7,109
Granted		85,000			9.69
Exercised		(40,000	)		6.11		132
Expired/cancelled		(13,474	)		6.54
Forfeited		—			—
Balances at March 31, 2021		1,421,094		$	5.60	$	5,589

Information about stock options outstanding, vested and expected to vest as of March 31, 2021, is as follows:

			Outstanding, Vested and Expected to Vest						Options Vested and Exercisable
Per Share Exercise Price			Shares		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life (Years)
$2.00	-	$2.99		120,500		4.7	$	2.41		120,500		4.7
$3.00	-	$3.99		17,500		6.0		3.84		17,500		6.0
$4.00	-	$4.99		938,567		8.2		4.51		680,974		7.9
$5.00	-	$9.99		274,527		7.4		8.03		198,216		6.7
$10.00	-	$27.06		70,000		4.0		16.62		50,000		1.6
				1,421,094		7.5	$	5.60		1,067,190		7.0

12.

Related Party Transaction

During 2021, we have engaged a consulting firm owned by our Vice President of Regulatory Affairs to perform certain tasks supporting our quality and regulatory activities. The work is performed as required by us and all services are invoiced on an hourly basis with no minimum commitment. Total charges invoiced were approximately $107,000 during the three-months ended March 31, 2021, and are recorded as research and development expenses, of which approximately $52,000 was outstanding and included in accounts payable as of March 31, 2021.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon accounting principles generally accepted in the United States of America and discusses the financial condition and results of operations for DiaMedica Therapeutics Inc. and its subsidiaries for the three months ended March 31, 2021 and 2020.

This discussion should be read in conjunction with our condensed consolidated financial statements and related notes included elsewhere in this report and our Annual Report on Form 10-K for the year ended December 31, 2020, which includes additional information about our critical accounting policies and practices and risk factors. The following discussion contains forward-looking statements that involve numerous risks and uncertainties. Our actual results could differ materially from the forward-looking statements as a result of these risks and uncertainties. See “Cautionary Note Regarding Forward-Looking Statements” for additional cautionary information.

Business Overview

We are a clinical stage biopharmaceutical company primarily focused on developing novel treatments for neurological disorders and kidney diseases. Currently, our primary focus is on developing DM199, a proprietary recombinant KLK1 protein for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Our goal is to use our patented and licensed technologies to establish our Company as a leader in the development and commercialization of therapeutic treatments from novel recombinant proteins. We plan to advance DM199, our lead drug candidate, through required clinical trials to create shareholder value by establishing its clinical and commercial potential as a therapy for AIS and CKD.

DM199 is a recombinant form of human tissue kallikrein-1 (KLK1). KLK1 is a serine protease (protein) produced primarily in the kidneys, pancreas and salivary glands, which plays a critical role in the regulation of local blood flow and vasodilation (the widening of blood vessels which decreases blood pressure) in the body, as well as an important role in inflammation and oxidative stress (an imbalance between potentially damaging reactive oxygen species, or free radicals, and antioxidants in the body). We believe DM199 has the potential to treat a variety of diseases where healthy functioning requires sufficient activity of KLK1 and its system, the kallikrein-kinin system.

Our DM199 product candidate is in clinical development as follows:

AIS Phase 2/3 ReMEDy2 Study

In December 2020, we received written responses from the FDA following a Type B Pre-IND meeting request that we submitted in October 2020 regarding our development plan for DM199 in the treatment of AIS. In the FDA’s written responses to the questions we provided, the FDA agreed with our proposals regarding key elements of a Phase 2/3 trial for DM199 in patients with AIS, including plans for an adaptive trial design with a primary endpoint based upon the modified Rankin Scale at day 90 and acknowledged that, provided the study results qualify, a single trial may support a Biologics License Application submission. Additionally, based upon the clinical and preclinical testing performed to date and currently in process, the FDA did not recommend any additional studies in preparation for an IND submission and initiation of our planned Phase 2/3 trial. We have filed an IND for this study and anticipate initiation of enrollment later this summer.

REDUX Clinical Trial

In October 2019, the U.S. Food and Drug Administration (FDA) accepted our Phase 2 clinical trial protocol for the treatment of CKD caused by rare or significant unmet diseases. The trial named REDUX, Latin for restore, is a multi-center, open-label investigation targeting enrollment of approximately 90 participants with mild or moderate CKD (Stage II or III) and albuminuria, who are being enrolled in three equal cohorts. The study is being conducted in the United States at 13 sites and is focused on participants with CKD: Cohort I is focused on non-diabetic, hypertensive African Americans with Stage II or III CKD. African Americans are at greater risk for CKD than Caucasians, and those African Americans who have the APOL1 gene mutation are at an even higher risk. The study is designed to capture the APOL1 gene mutation as an exploratory biomarker in this cohort. Cohort II is focused on participants with IgA Nephropathy. Cohort III, which was added after the completion of our August 2020 public offering, is focused on participants with Type 2 diabetes mellitus with CKD, hypertension and albuminuria. The study will evaluate two dose levels of DM199 within each cohort. Study participants receive DM199 by subcutaneous injection twice weekly for 95 days. The primary study endpoints include safety, tolerability, blood pressure, albuminuria and kidney function, which will be evaluated by changes from baseline in estimated glomerular filtration rate and albuminuria, as measured by the urinary albumin to creatinine ratio. Participant enrollment and dosing for this study commenced in December 2019.

As of April 30, 2021, we had enrolled 70 subjects, including 17 African American subjects into Cohort I, 21 subjects with IgAN into Cohort II and 32 subjects with Type 2 diabetes, hypertension and albuminuria into Cohort III of the REDUX study. Due to restrictions implemented at our clinical study sites to combat the COVID-19 pandemic, we have continued to experience slower than expected enrollment in the first two cohorts of the REDUX trial. We believe this is due to the reduction or suspension of activities at our clinical study sites as they address staff and patient safety concerns and patient concerns related to visiting clinical study sites in light of the COVID-19 pandemic. However, with the significant declines in new COVID-19 cases and the availability and effectiveness of vaccines, we currently anticipate completion of Cohort I and Cohort II in the second half of 2021. The enrollment of Cohort III was much more rapid completing in December 2020, which is likely due to the large population of potential subjects. We currently expect topline results from Cohort III to be available during the second quarter of 2021.

Financial Overview

We have not generated any revenues from product sales. Since our inception, we have financed our operations from public and private sales of equity, the exercise of warrants and stock options, interest income on funds available for investment and government grants. We have incurred losses in each year since our inception. We have incurred losses in each year since our inception. Our net losses were $3.6 million and $2.4 million for the three months ended March 31, 2021 and 2020, respectively. As of March 31, 2021, we had an accumulated deficit of $72.5 million. Substantially all of our operating losses resulted from expenses incurred in connection with the development of our DM199 product candidate, our primary research and development (R&D) activities, and general and administrative (G&A) support costs associated with our operations.

We expect to continue to incur significant expenses and increased operating losses for at least the next several years. In the near term, we anticipate that our expenses will increase as we:

●

complete our ongoing Phase 2 study of DM199 for CKD;

●

initiate and complete our pending Phase 2/3 study of DM199 for AIS;

●

complete manufacturing process development to support applications for commercial approval of DM199;

●

provide G&A support for our operations; and

●

maintain, expand and protect our intellectual property portfolio.

While we expect our rate of future negative cash flow per month will vary due to the timing of expenses incurred, we expect our current cash and marketable securities resources will be sufficient to allow us to complete all three cohorts in our REDUX Phase 2 study in patients with CKD, initiate our pending Phase 2/3 study in patients with AIS and to otherwise fund our planned operations for at least the next twelve months from the date of issuance of the financial statements included in this report. However, the amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing development efforts, including enrollment in our clinical trials, the potential expansion of our current development programs, potential new development programs, related G&A support and the effects of the COVID-19 pandemic. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time. We may elect to raise additional funds even before we need them if market conditions for raising additional capital are favorable.

Overview of Expense Components

Research and Development Expenses

R&D expenses consist primarily of fees paid to external service providers such as contract research organizations; contractual obligations for clinical development including clinical sites, outside nursing services and laboratory testing, and preclinical trials; development of manufacturing processes, costs for production runs of DM199; salaries, benefits, and share-based compensation and other personnel costs.

At this time, due to the risks inherent in the clinical development process and the clinical stage of our product development programs, we are unable to estimate with any certainty the costs we will incur in the continued development of DM199 or any of our preclinical development programs. Although as previously discussed, we have experienced a delay and expect to continue to expect a delay in the timing of costs incurred in the REDUX trial as a result of the COVID-19 pandemic, we do not expect to experience a significant overall increase in costs. We intend to continue to assess the effect of the pandemic on our REDUX trial and our future trials by monitoring the spread of the COVID-19 virus and the actions implemented to combat the virus. We expect that our R&D expenses will increase in the future if we are successful in advancing DM199, or any of our preclinical programs, into advanced stages of clinical development. The process of conducting clinical trials necessary to obtain regulatory approval and manufacturing scale-up to support expanded development and potential future commercialization is costly and time consuming. Any failure by us or delay in completing clinical trials, manufacturing scale-up or in obtaining regulatory approvals could lead to increased R&D expenses and, in turn, have a material adverse effect on our results of operations.

General and Administrative Expenses

G&A expenses consist primarily of salaries and related benefits, including share-based compensation related to our executive, finance, business development and support functions. Other G&A expenses include insurance, rent and utilities, travel expenses, patent costs and professional fees for auditing, tax and legal services. We expect our G&A expenses will continue to increase in the future as we expand our development and operating activities.

We have instituted a number of procedural changes related to protecting the health and safety of our employees in response to the COVID-19 pandemic.Our office was closed in the second quarter of 2020 and remained closed during the first quarter of 2021 and our employees worked remotely. In addition, all non-essential travel was on hold. We have encouraged our employees to interact with each other and vendors through audio and video conferencing. We did not incur significant additional G&A expenses during the first quarter of 2021 related to these changes, nor do we expect to incur significant additional G&A expenses going forward. We expect to continue to work remotely and restrict non-essential travel for the foreseeable future.

Other (Income) Expense

Other (income) expense consists primarily of interest income and foreign currency exchange gains and losses. In past years governmental assistance – research incentives, which were associated with the ReMEDy Phase 2 stroke study, were a significant component of this line item.

Results of Operations

Comparison of the Three Months ended March 31, 2021 and 2020

The following table summarizes our unaudited results of operations for the three months ended March 31, 2021 and 2020 (in thousands):

	Three Months Ended March 31,
	2021		2020
Operating expenses:
Research and development	$	2,406	$	1,349
General and administrative		1,213		1,055

Research and Development Expenses

R&D expenses were $2.4 million for the three months ended March 31, 2021, compared with $1.4 million for the three months ended March 31, 2020, an increase of $1.0 million. The increase was due to a number of factors including a year-over-year increase in costs incurred for our REDUX Phase 2 CKD study, and costs associated with an increase in staff levels, consulting services and non-clinical testing required to support preparation for our ReMEDy2 Phase 2/3 stroke study. These increases were partially offset by a year-over-year decrease in costs incurred for our ReMEDy Phase 2 stroke study which completed during 2020.

General and Administrative Expenses

G&A expenses were $1.2 million for the three months ended March 31, 2021, up from $1.1 million for the three months ended March 31, 2020. The increase in G&A expenses resulted primarily from increased directors and officers liability insurance, personnel and non-cash share-based compensation costs.

Liquidity and Capital Resources

The following tables summarize our liquidity and capital resources as of March 31, 2021 and December 31, 2020, and our sources and uses of cash for each of the three month periods ended March 31, 2021 and 2020, and is intended to supplement the more detailed discussion that follows (in thousands):

Liquidity and Capital Resources	March 31, 2021		December 31, 2020
Cash, cash equivalents and marketable securities	$	23,400	$	27,507
Total assets		24,356		28,095
Total current liabilities		1,178		2,028
Total shareholders’ equity		23,145		26,014
Working capital		23,017		25,893

	Three Months Ended March 31,
Cash Flow Data	2021			2020
Cash flow provided by (used in):
Operating activities	$	(4,313	)	$	(2,978	)
Investing activities		(9	)		(5,301	)
Financing activities		242			7,696
Net decrease in cash	$	(4,080	)	$	(583	)

Working Capital

We had cash and cash equivalents of $3.3 million, marketable securities of $20.1 million, current liabilities of $1.2 million and working capital of $23.0 million as of March 31, 2021, compared to $7.4 million in cash and cash equivalents, marketable securities of $20.1 million, $2.0 million in current liabilities and $25.9 million in working capital as of December 31, 2020. The decreases in our combined cash, cash equivalents and marketable securities and in our working capital are due primarily to our increased clinical study costs related to our REDUX Phase 2 CKD study and costs associated with preparing for our ReMEDy2 Phase 2/3 stroke study.

Cash Flows

Operating Activities

Net cash used in operating activities for the three months ended March 31, 2021 was $4.3 million compared to $3.0 million for the three months ended March 31, 2020. This increase relates primarily to the increase in the net loss, partially offset by the effects of the changes in operating assets and liabilities.

Investing Activities

Investing activities consist primarily of purchases and maturities of marketable securities. Net cash used in investing activities was $9,000 for the three months ended March 31, 2021 compared to $5.3 million for the three months ended March 31, 2020.

Financing Activities

Financing activities in the current year consisted primarily of net proceeds from the exercise of stock options and from the sale of common shares in the prior year period. Net cash provided by financing activities was $0.2 million and $7.7 million for the three months ended March 31, 2021 and 2020, respectively.

Capital Requirements

Since our inception, we have incurred losses while advancing the R&D of our DM199 product candidate. We have not generated any revenues from product sales and do not expect to do so for at least three to five years. We do not know when, or if, we will generate any revenues from product sales of our DM199 product candidate or any future product candidate. We do not expect to generate any revenue from product sales unless and until we obtain regulatory approval. We expect to continue to incur substantial operating losses until such time as any future product sales, royalty payments, licensing fees and/or milestone payments are sufficient to generate revenues to fund our continuing operations. We expect our operating losses to increase in the near term as we continue the research, development and clinical trials of, and seek regulatory approval for, our DM199 product candidate. In the long-term, subject to obtaining regulatory approval of our DM199 product candidate or any future product candidate and in the absence of the assistance of a strategic partner, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution.

Accordingly, we expect we will need substantial additional capital to further our R&D activities, planned clinical trials, regulatory activities and otherwise develop our product candidate, DM199, or any future product candidates, to a point where they may be commercially sold. Although we are striving to achieve these plans, there is no assurance these and other strategies will be achieved or that additional funding will be obtained on favorable terms or at all. While our rate of future negative cash flow per month will vary due to the timing of expenses incurred, we expect our current cash resources will be sufficient to allow us to complete all three cohorts in our REDUX Phase 2 study in patients with CKD, initiate our pending Phase 2/3 study in patients with AIS and to otherwise fund our planned operations for at least the next twelve months from the date of issuance of the financial statements included in this report. However, the amount and timing of future funding requirements will depend on many factors, including the timing and results of our ongoing development efforts, the potential expansion of current development programs, potential new development programs and related G&A support. We may require significant additional funds earlier than we currently expect and there is no assurance that we will not need or seek additional funding prior to such time, especially if market conditions for raising additional capital are favorable.

Since our inception, we have financed our operations from public and private sales of equity, the exercise of warrants and stock options, interest income on funds available for investment and government incentive grants, and we expect to continue this practice for the foreseeable future. We do not have any existing credit facilities under which we could borrow funds. We may seek to raise additional funds through various sources, such as equity or debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or on terms acceptable to us. This is particularly true if our clinical data is not positive or economic and market conditions deteriorate.

To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our shareholders will be diluted. Debt financing, if available, may involve agreements that include conversion discounts or covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through government or other third-party funding, marketing and distribution arrangements or other collaborations, or strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. The availability of financing will be affected by our clinical data and other results of scientific and clinical research; the ability to attain regulatory approvals; market acceptance of our product candidates; the state of the capital markets generally with particular reference to pharmaceutical, biotechnology and medical companies; the status of strategic alliance agreements; and other relevant commercial considerations.

If adequate funding is not available, we may be required to implement cost reduction strategies; delay, reduce, or eliminate one or more of our product development programs; relinquish significant rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us; and/or divest assets or cease operations through a merger, sale, or liquidation of our Company.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements (as defined by applicable SEC regulations) that could have a current material effect or that are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures or capital resources.

Critical Accounting Policies and Estimates

There have been no material changes to our critical accounting policies and estimates from the information provided in “Part II. Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies,” included in our annual report on Form 10-K for the fiscal year ended December 31, 2020.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a smaller reporting company, we are not required to provide disclosure pursuant to this item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the United States Securities Exchange Act of 1934, as amended (Exchange Act)) that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management evaluated, with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered in this report. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective as of the end of such period to provide reasonable assurance that information required to be disclosed in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting that occurred during the three months ended March 31, 2021 that has materially affected or is reasonably likely to materially affect our internal control over financial reporting.

PART II -

OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

In March 2013, we entered into a clinical research agreement with PRA Netherlands to perform a double-blinded, placebo-controlled, single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and proof of concept of DM199 in healthy subjects and in patients with Type 2 diabetes mellitus. In one arm of this study, we enrolled 36 patients with Type 2 diabetes who were treated with two subcutaneous dose levels of DM199 over a 28-day period. This study achieved its primary endpoint and demonstrated that DM199 was well-tolerated. The secondary endpoints for this study, however, were not met. The secondary efficacy endpoints were confounded due to what we believe were significant execution errors caused by protocol deviations occurring at the clinical trial site that were unable to be reconciled. To date, we have been unable to obtain the complete study records from PRA Netherlands and generate a final study report. On November 14, 2017, we initiated litigation with PRA Netherlands in the United States District Court, Southern District of New York, to compel PRA Netherlands to comply with the terms of the clinical research agreement, including providing full study records and to recover damages. After PRA Netherlands objected to personal jurisdiction and venue, on August 24, 2018, we re-filed our complaint against both PRA Netherlands and its U.S. parent, PRA Health Sciences, Inc. (PRA USA and collectively with PRA Netherlands, PRA), in the United States District Court, District of Delaware. PRA again objected to the venue and personal jurisdiction. The complaint alleges, among other things, that PRA failed to conduct the study in accordance with the study protocol and with generally accepted standards for conducting such clinical trials and that PRA further refused to provide us with all data, records and documentation, and/or access thereto, related to the study in accordance with the clinical trial study agreement. The complaint sought to compel PRA to comply with the terms of the clinical trial study agreement, including providing full study records and to recover damages. On November 19, 2018, PRA Netherlands and PRA USA filed motions to dismiss the lawsuit. On February 20, 2019, we filed a motion seeking to transfer the Delaware action to the United States District Court, District of Minnesota. PRA Netherlands and PRA USA filed an opposition to our motion. On September 21, 2020, the District Court judge issued a ruling denying our motion to transfer indicating that DiaMedica had not met the required standards to support a venue transfer. We believe that, based upon the rationale utilized in the opinion, that the case will likely be dismissed for lack of personal jurisdiction over PRA Netherlands. On November 2, 2020, a final dismissal order was issued by the District Court judge. Due to the uncertainty inherent in appealing this ruling, we have chosen to cease action in the United States and file our claims against PRA Netherlands directly in a Dutch Court. On November 13, 2020, PRA Netherlands was served with our complaint. PRA Netherlands and PRA USA filed their initial appearances with the Dutch Court on February 24, 2021, and are due to submit their defense, bringing forward all procedural and substances defenses. However, before that time, we intend to file a motion to move the case to the Netherlands Commercial Court (NCC), which specializes in handling international commercial disputes and provides more flexibility to accommodate the specific needs of an individual case. If the case is moved to the NCC, the existing deadlines could change.

From time to time, we may be subject to other various ongoing or threatened legal actions and proceedings, including those that arise in the ordinary course of business, which may include employment matters and breach of contract disputes. Such matters are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. Other than the PRA matter noted above, we are not currently engaged in or aware of any threatened legal actions.

ITEM 1A.

RISK FACTORS

As a smaller reporting company, we are not required to provide disclosure pursuant to this item.

ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

We did not sell any unregistered equity securities of our Company during the quarter ended March 31, 2021.

ITEM 3.

DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4.

MINE SAFETY DISCLOSURES

Not applicable.

ITEM 5.

OTHER INFORMATION

Not applicable.

ITEM 6.

EXHIBITS

The following exhibits are being filed or furnished with this quarterly report on Form 10-Q:

Exhibit No.	Description	Manner of Filing
3.1	Notice of Articles of DiaMedica Therapeutics Inc. dated May 31, 2019	Incorporated by reference to Exhibit 3.1 to DiaMedica’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 4, 2019 (File No. 001-36291)
3.2	Articles of DiaMedica Therapeutics Inc. dated May 31, 2019	Incorporated by reference to Exhibit 3.2 to DiaMedica’s Current Report on Form 8-K as filed with the Securities and Exchange Commission on June 4, 2019 (File No. 001-36291)
31.1	Certification of Chief Executive Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
31.2	Certification of Chief Financial Officer Pursuant to Exchange Act Rules 13a-14(a)/15d-14(a), as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed herewith
32.1	Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
32.2	Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Furnished herewith
101	Financial statements from the quarterly report on Form 10-Q of DiaMedica Therapeutics Inc. for the quarter ended March 31, 2021, formatted in XBRL: (i) the Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations and Comprehensive Loss, (iii) Condensed Consolidated Statements of Shareholders’ Equity, (iv) Condensed Consolidated Statements of Cash Flows, and (v) Notes to the Condensed Consolidated Financial Statements.	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	DIAMEDICA THERAPEUTICS INC.

Date: May 5, 2021	/s/ Rick Pauls
	Rick Pauls President and Chief Executive Officer
	(Principal Executive Officer)

Date: May 5, 2021	/s/ Scott Kellen
	Scott Kellen Chief Financial Officer
	(Principal Financial Officer and Principal Accounting Officer)

EX-31.1 2 ex_246297.htm EXHIBIT 31.1 ex_246297.htm

Exhibit 31.1

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Rick Pauls, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of DiaMedica Therapeutics Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 5, 2021		/s/ Rick Pauls
		Rick Pauls
		President and Chief Executive Officer
		(Principal Executive Officer)

EX-31.2 3 ex_246298.htm EXHIBIT 31.2 ex_246298.htm

Exhibit 31.2

CERTIFICATION PURSUANT TO RULE 13a-14(a) OR 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF 1934, AS AMENDED, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Scott Kellen, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of DiaMedica Therapeutics Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.	The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

	a.	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b.	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c.	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d.	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

	a.	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
	b.	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: May 5, 2021		/s/ Scott Kellen
		Scott Kellen
		Chief Financial Officer
		(Principal Financial Officer)

EX-32.1 4 ex_246299.htm EXHIBIT 32.1 ex_246299.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Rick Pauls, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	the Quarterly Report on Form 10-Q of DiaMedica Therapeutics Inc. for the quarter ended March 31, 2021 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of DiaMedica Therapeutics Inc.

Dated: May 5, 2021

	/s/ Rick Pauls
	Rick Pauls
	President and Chief Executive Officer
	(Principal Executive Officer)

EX-32.2 5 ex_246300.htm EXHIBIT 32.2 ex_246300.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Scott Kellen, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1)	the Quarterly Report on Form 10-Q of DiaMedica Therapeutics Inc. for the quarter ended March 31, 2021 (the Report) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)	the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of DiaMedica Therapeutics Inc.

Dated: May 5, 2021

	/s/ Scott Kellen
	Scott Kellen
	Chief Financial Officer
	(Principal Financial Officer)

EX-101.INS 6 dmac-20210331.xml XBRL INSTANCE DOCUMENT false --12-31 Q1 2021 2021-03-31 10-Q 0001401040 18786157 Yes true true Non-accelerated Filer Yes DiaMedica Therapeutics Inc. false true Voting common shares, no par value per share dmac 237000 13000 143000 360000 7000 8000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31, 2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 85%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options outstanding</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">1,421,094</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred share units outstanding</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">72,142</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">1,050,026</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">265,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">2,808,262</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="30" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Fair Value Measurements Using Inputs Considered as of:</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31, 2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td colspan="14" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level</div> <div style="display: inline; font-weight: bold;">1</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level</div> <div style="display: inline; font-weight: bold;">3</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 1</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 2</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Level 3</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 20%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Government securities</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,004</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,004</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8,924</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">8,924</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Bank certificates of deposit</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">245</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">245</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">496</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">496</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper and corporate bonds</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">13,823</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">13,823</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">10,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">10,678</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,072</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,072</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,098</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,098</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 7%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div> 115000 14000 13000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Patent costs</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Costs associated with applying for, prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, the resulting probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in general and administrative costs and were <div style="display: inline; font-style: italic; font: inherit;">$48,000</div> and <div style="display: inline; font-style: italic; font: inherit;">$32,000</div> for the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021 </div>and <div style="display: inline; font-style: italic; font: inherit;">2020,</div> respectively.</div></div></div></div></div></div></div></div> 48000 32000 7700000 289000 289000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div></div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Risks and Uncertainties</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DiaMedica operates in a highly regulated and competitive environment. The development, manufacturing and marketing of pharmaceutical products require approval from, and are subject to ongoing oversight by, the Food and Drug Administration (FDA) in the United States, the European Medicines Agency (EMA) in the European Union and comparable agencies in other countries. We are in the clinical stage of development of our initial product candidate, <div style="display: inline; font-style: italic; font: inherit;">DM199,</div> for the treatment of AIS and CKD. The Company has <div style="display: inline; font-style: italic; font: inherit;">not</div> completed the development of any product candidate and, accordingly, has <div style="display: inline; font-style: italic; font: inherit;">not</div> begun to commercialize any product candidate or generate any revenues from the commercial sale of any product candidate. <div style="display: inline; font-style: italic; font: inherit;">DM199</div> requires significant additional clinical testing and investment prior to seeking marketing approval and is <div style="display: inline; font-style: italic; font: inherit;">not</div> expected to be commercially available for at least <div style="display: inline; font-style: italic; font: inherit;">three</div> to <div style="display: inline; font-style: italic; font: inherit;">five</div> years, if at all. The Company's future success is dependent upon the success of its development efforts, its ability to demonstrate clinical progress for its <div style="display: inline; font-style: italic; font: inherit;">DM199</div> product candidate in the United States or other markets, its ability to obtain required governmental approvals of its product candidate, its ability to license or market and sell its <div style="display: inline; font-style: italic; font: inherit;">DM199</div> product candidate and its ability to obtain additional financing to fund these efforts.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>we have incurred losses of <div style="display: inline; font-style: italic; font: inherit;">$72.5</div> million since our inception in <div style="display: inline; font-style: italic; font: inherit;">2000.</div> For the <div style="display: inline; font-style: italic; font: inherit;">three</div> months ended <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>we incurred a net loss of <div style="display: inline; font-style: italic; font: inherit;">$3.6</div> million and negative cash flows from operating activities of <div style="display: inline; font-style: italic; font: inherit;">$4.3</div> million. We expect to continue to incur operating losses until such time as any future product sales, royalty payments, licensing fees, and/or milestone payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical trials of, and to seek regulatory approval for, our <div style="display: inline; font-style: italic; font: inherit;">DM199</div> product candidate. As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>DiaMedica had cash and cash equivalents of <div style="display: inline; font-style: italic; font: inherit;">$3.3</div> million, marketable securities of <div style="display: inline; font-style: italic; font: inherit;">$20.1</div> million, working capital of <div style="display: inline; font-style: italic; font: inherit;">$23.0</div> million and shareholders' equity of <div style="display: inline; font-style: italic; font: inherit;">$23.1</div> million. Our principal source of cash has been net proceeds from the issuance of equity securities. Although the Company has previously been successful in obtaining financing through equity securities offerings, there is <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance that we will be able to do so in the future. This is particularly true if our clinical data is <div style="display: inline; font-style: italic; font: inherit;">not</div> positive or economic and market conditions deteriorate.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that we will need substantial additional capital to further our research and development activities, complete the required clinical trials and regulatory activities and otherwise develop our product candidate, <div style="display: inline; font-style: italic; font: inherit;">DM199,</div> or any future product candidates, to a point where they <div style="display: inline; font-style: italic; font: inherit;"> may </div>be commercially sold. We expect our current cash, cash equivalents and marketable securities, to be sufficient to allow us to complete our currently ongoing Phase <div style="display: inline; font-style: italic; font: inherit;">2</div> study in patients with CKD and to otherwise fund our planned operations for at least the next <div style="display: inline; font-style: italic; font: inherit;">twelve</div> months from the date of issuance of these financial statements. However, the amount and timing of our future funding requirements will depend on many factors, including the timing and results of ongoing development efforts, the potential expansion of current development programs, potential new development programs and related general and administrative support. We <div style="display: inline; font-style: italic; font: inherit;"> may </div>require significant additional funds earlier than we currently expect and there is <div style="display: inline; font-style: italic; font: inherit;">no</div> assurance that we will <div style="display: inline; font-style: italic; font: inherit;">not</div> need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div></div> 0 0 23000000

420000

864000

689000

1099000

52000

337000

340000

420000

864000

48000

57000

-4000

-2000

95680000

94925000

819000

131000

107000

380000

286000

511000

393000

1421094

1181309

265000

255000

72142

21183

24356000

28095000

24195000

27921000

161000

174000

6004000

8924000

245000

496000

13823000

10678000

20072000

20098000

3329000

7409000

3300000

7409000

3883000

3329000

3300000

-4080000

-583000

50959

21183

1493234

1421094

72142

1050026

265000

2808262

Unlimited

18786157

18746157

18786157

18746157

-3624000

-2385000

6000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 36pt;"> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">11.</div></div></div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: "Times New Roman"; font-size: 10pt;"><div style="display: inline; font-weight: bold;">Share-Based Compensation</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2019</div> Omnibus Incentive Plan</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DiaMedica Therapeutics Inc. <div style="display: inline; font-style: italic; font: inherit;">2019</div> Omnibus Incentive Plan (<div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan) was adopted by the Board of Directors in <div style="display: inline; font-style: italic; font: inherit;"> March 2019 </div>and approved by our shareholders at our annual general and special meeting of shareholders held on <div style="display: inline; font-style: italic; font: inherit;"> May 22, 2019. </div>The <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company's eligible employees, non-employee directors and consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards and other stock-based awards. We grant options to purchase common shares under the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan at <div style="display: inline; font-style: italic; font: inherit;">no</div> less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of <div style="display: inline; font-style: italic; font: inherit;">ten</div> years and generally vest in approximately equal quarterly installments over <div style="display: inline; font-style: italic; font: inherit;">one</div> to <div style="display: inline; font-style: italic; font: inherit;">three</div> years. Options granted to non-employees have a maximum term of <div style="display: inline; font-style: italic; font: inherit;">five</div> years and generally vest in approximately equal quarterly installments over <div style="display: inline; font-style: italic; font: inherit;">one</div> year. Subject to adjustment as provided in the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan, the maximum number of the Company's common shares authorized for issuance under the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan is <div style="display: inline; font-style: italic; font: inherit;">2,000,000</div> shares. As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>options to purchase <div style="display: inline; font-style: italic; font: inherit;">930,684</div> common shares were outstanding and <div style="display: inline; font-style: italic; font: inherit;">50,959</div> common shares were reserved for issuance upon settlement of deferred share units (DSUs) under the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Prior stock option plan</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated <div style="display: inline; font-style: italic; font: inherit;"> November 6, 2018 (</div>Prior Plan), was terminated by the Board of Directors in conjunction with the shareholder approval of the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan. As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>options to purchase <div style="display: inline; font-style: italic; font: inherit;">490,410</div> common shares were outstanding under the Prior Plan.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As the TSX Venture Exchange was the principal trading market for the Company's common shares, all options granted prior to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2018 </div>were priced in Canadian dollars. Options granted after <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2018 </div>have been priced in United States dollars.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Prior deferred share unit plan</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan (DSU Plan) was terminated by the Board of Directors in conjunction with the shareholder approval of the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan. Awards outstanding under the DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>there were <div style="display: inline; font-style: italic; font: inherit;">21,183</div> common shares reserved for DSUs outstanding.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The aggregate number of common shares reserved for issuance for awards granted under the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Plan, the Prior Plan and the DSU Plan as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021 </div>was <div style="display: inline; font-style: italic; font: inherit;">1,493,234.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Share-based compensation expense for each of the periods presented is as follows (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">131</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">107</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">380</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">393</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We recognize share-based compensation based on the fair value of each award as estimated using the Black-Scholes option valuation model. Ultimately, the actual expense recognized over the vesting period will only be for those shares that actually vest.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A summary of option activity is as follows (in thousands except share and per share amounts):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div> <table cellpadding="0pt" cellspacing="0pt" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Underlying</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average Exercise</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Price Per Share</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Aggregate</div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Intrinsic Value</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balances at December 31, 2020</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,389,568</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5.38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,109</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">85,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 15%;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Exercised</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(40,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">132</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Expired/cancelled</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(13,474</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 15%;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">—</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 15%;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 46%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balances at March 31, 2021</div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,421,094</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5,589</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information about stock options outstanding, vested and expected to vest as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>is as follows:</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div> <table cellpadding="0pt" cellspacing="0pt" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 32%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding, Vested and Expected to Vest</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options Vested and Exercisable</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td colspan="3" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 6%; border-bottom: 1px solid black;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Per Share Exercise </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Price</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual Life </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercisable</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual Life </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$2.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$2.99</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">120,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">120,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$3.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$3.99</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">17,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.84</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">17,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$4.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$4.99</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">938,567</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.51</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">680,974</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$5.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$9.99</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">274,527</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8.03</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">198,216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$10.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$27.06</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">70,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">16.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,421,094</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,067,190</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table> </div></div>

-0.19

33000

483000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Fair value measurements</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The hierarchy is broken down into <div style="display: inline; font-style: italic; font: inherit;">three</div> levels defined as follows:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><div style="display: inline; font-style: italic;">Level <div style="display: inline; font-style: italic; font: inherit;">1</div> Inputs</div> — quoted prices in active markets for identical assets and liabilities</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><div style="display: inline; font-style: italic;">Level <div style="display: inline; font-style: italic; font: inherit;">2</div> Inputs</div> — observable inputs other than quoted prices in active markets for identical assets and liabilities</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;"><div style="display: inline; font-style: italic;">Level <div style="display: inline; font-style: italic; font: inherit;">3</div> Inputs</div> — unobservable inputs</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021, </div>the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note <div style="display: inline; font-style: italic; font: inherit;">4,</div> titled “<div style="display: inline; font-style: italic;">Marketable Securities</div>” for additional information.</div></div></div></div></div></div></div></div>

6000

5000

7000

2000

1213000

1055000

-3615000

-2416000

7000

9000

4000

2000

-410000

262000

-3000

162000

-458000

-654000

383000

397000

37000

34000

-26000

14000

0.09

97000

46000

51000

6000

24356000

28095000

1178000

2028000

33000

53000

20100000

20072000

20098000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">Marketable securities</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company's marketable securities typically consist of obligations of the United States government and its agencies, investment grade corporate obligations and bank certificates of deposit, which are classified as available-for-sale and included in current assets as they are intended to fund current operations. Securities are valued based on market prices for similar assets using <div style="display: inline; font-style: italic; font: inherit;">third</div> party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of shareholders' equity in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method and are included in other income in the condensed consolidated statements of operations.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that <div style="display: inline; font-style: italic; font: inherit;"> may </div>indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> be forced to sell the security before recovering its cost, or (iii) does <div style="display: inline; font-style: italic; font: inherit;">not</div> expect to recover the security's amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of shareholders' equity in accumulated other comprehensive income (loss). There were <div style="display: inline; font-style: italic; font: inherit;">no</div> other-than-temporary unrealized losses as of <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2021.</div></div></div></div></div></div></div></div></div>

242000

7696000

-9000

-5301000

-4313000

-2978000

-3622000

-2425000

4000

-12000

-3619000

-2404000

17000

91000

63000

59000

28000

46000

86000

100000

-2000

40000

4000

-127000

44000

49000

11923000

8799000

9000

2000

457000

74000

8500000

7682000

11921000

3500000

2000

244000

16000

61000

69000

62000

123000

131000

75000

74000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31, 2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">61</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">123</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">131</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(48</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(57</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Property and equipment, net</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">75</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

107000

2406000

1349000

-72531000

-68909000

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31, 2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development incentives</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">289</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">289</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales-based taxes receivable</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">44</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">49</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total amounts receivable</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">337</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">340</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31, 2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical study costs</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 1pt;">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 1pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">237</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">13</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued research and other professional fees</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">143</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">360</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">483</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued taxes and other liabilities</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total accrued liabilities</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">420</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">864</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Employee and non-employee stock options</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,421,094</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,181,309</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under common share purchase warrants</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">265,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">255,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common shares issuable under deferred unit awards</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">72,142</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21,183</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31,</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(3,622</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,425</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</div> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding—basic and diluted</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">18,766,656</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">13,107,725</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Basic and diluted net loss per share</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.19</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.19</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</div> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: "Times New Roman"; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Three Months Ended</div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">March 31</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2021</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: "Times New Roman"; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt; width: 70%;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">131</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">107</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">380</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">286</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman"; font-size: 10pt;"> <div style=" font-family: "Times New Roman"; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total share-based compensation</div> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">511</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">393</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

<div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="10" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 32%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Outstanding, Vested and Expected to Vest</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 18%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options Vested and Exercisable</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> <td colspan="3" rowspan="1" style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 6%; border-bottom: 1px solid black;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Per Share Exercise </div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Price</div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual Life </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercise Price</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Options </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Exercisable</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted Average </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Remaining </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Contractual Life </div></div></div> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">(Years)</div></div></div> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$2.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$2.99</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">120,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">120,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$3.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$3.99</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">17,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.84</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">17,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$4.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$4.99</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">938,567</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8.2</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.51</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">680,974</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$5.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$9.99</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">274,527</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8.03</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">198,216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;">$10.00</td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"> <div style=" font-family: "Times New Roman", Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$27.06</div></div> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">70,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">16.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"> </td> </tr> <tr style="vertical-align: bottom; font-family: "Times New Roman", Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 4%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 2%;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 12%;"><div style="display: inline; font-style: italic; font: inherit;"> </div></td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 11%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,421,094</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.5</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,067,190</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </table></div>

511000

393000

P1Y

P3Y

P1Y

2000000

132000

13474

85000

7109000

5589000

930684

490410

1389568

1421094

5.38

5.60

6.11

6.54

9.69

120500

17500

680974

198216

50000

1067190

120500

17500

938567

274527

70000

1421094

2.99

3.99

4.99

9.99

27.06

P10Y

P5Y

P4Y255D

P6Y

P7Y328D

P6Y255D

P1Y219D

P7Y

2.41

3.84

4.51

8.03

16.62

5.60

P4Y255D

P6Y

P8Y73D

P7Y146D

P4Y

P7Y182D

18746157

18786157

12006874

14139074

511000

393000

2125000

40000

7200

40000

7200

40000

7682000

244000

16000

244000

16000

23145000

94925000

-2000

-68909000

26014000

95680000

-4000

-72531000

64232000

2000

-56617000

7617000

73323000

42000

-59042000

13323000

14000

18766656

13107725

xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember dmac:The2019OmnibusIncentivePlanMember 2019-03-01 2019-03-30 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember dmac:The2019OmnibusIncentivePlanMember srt:MaximumMember 2019-03-01 2019-03-30 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember dmac:The2019OmnibusIncentivePlanMember srt:MinimumMember 2019-03-01 2019-03-30 0001401040 dmac:NonemployeeStockOptionsMember dmac:The2019OmnibusIncentivePlanMember 2019-03-01 2019-03-30 0001401040 2020-01-01 2020-03-31 0001401040 dmac:DeferredShareUnitsMember 2020-01-01 2020-03-31 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember 2020-01-01 2020-03-31 0001401040 us-gaap:WarrantMember 2020-01-01 2020-03-31 0001401040 dmac:WarrantsIssuedInPrivatePlacementMember 2020-01-01 2020-03-31 0001401040 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-03-31 0001401040 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-03-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001401040 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001401040 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001401040 dmac:StockIssuanceMember 2020-01-01 2020-03-31 0001401040 2020-01-01 2020-12-31 0001401040 2020-02-13 2020-02-13 0001401040 2021-01-01 2021-03-31 0001401040 dmac:DeferredShareUnitsMember 2021-01-01 2021-03-31 0001401040 dmac:EmployeeAndNonemployeeStockOptionsMember 2021-01-01 2021-03-31 0001401040 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001401040 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-03-31 0001401040 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001401040 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001401040 us-gaap:ResearchAndDevelopmentExpenseMember dmac:ConsultingServicesMember srt:VicePresidentMember 2021-01-01 2021-03-31 0001401040 dmac:ExercisePriceRange1Member 2021-01-01 2021-03-31 0001401040 dmac:ExercisePriceRange2Member 2021-01-01 2021-03-31 0001401040 dmac:ExercisePriceRange3Member 2021-01-01 2021-03-31 0001401040 dmac:ExercisePriceRange4Member 2021-01-01 2021-03-31 0001401040 dmac:ExercisePriceRange5Member 2021-01-01 2021-03-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001401040 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001401040 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001401040 dmac:The2019OmnibusIncentivePlanMember 2019-03-30 0001401040 2019-12-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001401040 us-gaap:CommonStockMember 2019-12-31 0001401040 us-gaap:RetainedEarningsMember 2019-12-31 0001401040 2020-02-13 0001401040 2020-03-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001401040 us-gaap:CommonStockMember 2020-03-31 0001401040 us-gaap:RetainedEarningsMember 2020-03-31 0001401040 2020-12-31 0001401040 dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember 2020-12-31 0001401040 us-gaap:EmployeeStockOptionMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember dmac:BankCertificatesOfDepositMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember dmac:BankCertificatesOfDepositMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember dmac:BankCertificatesOfDepositMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2020-12-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember dmac:BankCertificatesOfDepositMember 2020-12-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2020-12-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-12-31 0001401040 us-gaap:ComputerEquipmentMember 2020-12-31 0001401040 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001401040 us-gaap:CommonStockMember 2020-12-31 0001401040 us-gaap:RetainedEarningsMember 2020-12-31 0001401040 2021-03-31 0001401040 dmac:AccruedInterestReceivableOnAvailableForSaleSecuritiesMember 2021-03-31 0001401040 dmac:CommonSharePurchaseWarrantsMember 2021-03-31 0001401040 dmac:DeferredShareUnitsMember 2021-03-31 0001401040 us-gaap:EmployeeStockOptionMember 2021-03-31 0001401040 dmac:StockOptionsOutstandingMember 2021-03-31 0001401040 dmac:The2019OmnibusIncentivePlanMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember dmac:BankCertificatesOfDepositMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember dmac:BankCertificatesOfDepositMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember dmac:BankCertificatesOfDepositMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2021-03-31 0001401040 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-03-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember 2021-03-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember dmac:BankCertificatesOfDepositMember 2021-03-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember dmac:CommercialPaperAndCorporateBondsMember 2021-03-31 0001401040 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2021-03-31 0001401040 dmac:StockOptionPriorPlanMember 2021-03-31 0001401040 dmac:The2012DSUPlanMember 2021-03-31 0001401040 dmac:The2019OmnibusIncentivePlanMember 2021-03-31 0001401040 dmac:The2019OmnibusIncentivePlanStockOptionPriorPlanAndThe2012DSUPlanMember 2021-03-31 0001401040 us-gaap:ComputerEquipmentMember 2021-03-31 0001401040 us-gaap:FurnitureAndFixturesMember 2021-03-31 0001401040 dmac:ConsultingServicesMember srt:VicePresidentMember 2021-03-31 0001401040 dmac:ExercisePriceRange1Member 2021-03-31 0001401040 dmac:ExercisePriceRange2Member 2021-03-31 0001401040 dmac:ExercisePriceRange3Member 2021-03-31 0001401040 dmac:ExercisePriceRange4Member 2021-03-31 0001401040 dmac:ExercisePriceRange5Member 2021-03-31 0001401040 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001401040 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001401040 us-gaap:CommonStockMember 2021-03-31 0001401040 us-gaap:RetainedEarningsMember 2021-03-31 0001401040 2021-05-03

EX-101.SCH 7 dmac-20210331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 1 - Business link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 2 - Risks and Uncertainties link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 3 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 4 - Marketable Securities link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 5 - Amounts Receivable link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 6 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 7 - Accrued Liabilities link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 8 - Operating Lease link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 9 - Shareholders' Equity link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 11 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 4 - Marketable Securities (Tables) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 5 - Amounts Receivable (Tables) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 6 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 7 - Accrued Liabilities (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 8 - Operating Lease (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 9 - Shareholders' Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 11 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 4 - Marketable Securities (Details Textual) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 5 - Amounts Receivable - Amounts Receivable (Details) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 6 - Property and Equipment - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 7 - Accrued Liabilities - Accrued Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 8 - Operating Lease (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 8 - Operating Lease - Maturity of Operating Lease Liability (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 9 - Shareholders' Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 9 - Shareholders' Equity - Shares Reserved (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 11 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 11 - Share-based Compensation - Share-based Compensation Expense (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 11 - Share-based Compensation - Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 11 - Share-based Compensation - Stock Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 8 dmac-20210331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 dmac-20210331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 dmac-20210331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value Measurement, Policy [Policy Text Block] Patent Costs [Policy Text Block] Disclosure of accounting policy for patent costs. Other us-gaap_OtherReceivables Note To Financial Statement Details Textual Significant Accounting Policies Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] 2022 Note 4 - Marketable Securities Note 5 - Amounts Receivable Employee and Non-employee Stock Options [Member] Related to employee and non-employee stock option awards. Note 6 - Property and Equipment Accrued taxes and other liabilities The amount of accrued taxes and other liabilities classified as current. dmac_PatentExpense Patent Expense The amount of expense associated with gaining and maintaining certain patents. Note 7 - Accrued Liabilities Accrued clinical study costs The amount of accrued clinical study costs classified as current. Note 8 - Operating Lease Research and development incentives The amount of research and development incentives receivable. Note 9 - Shareholders' Equity Non-current liabilities: Note 10 - Net Loss Per Share Note 11 - Share-based Compensation Non-cash lease expense Amount of expense recognized over the period for lease expense, non-cash. Deferred Share Units [Member] Related to deferred share units. Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) Unrealized gain (loss) on marketable securities Unrealized gain (loss) on marketable securities Note 5 - Amounts Receivable - Amounts Receivable (Details) Note 6 - Property and Equipment - Property and Equipment (Details) Lessee, Operating Lease, Liability, Maturity [Table Text Block] Note 7 - Accrued Liabilities - Accrued Liabilities (Details) Share-based compensation us-gaap_ShareBasedCompensation Note 8 - Operating Lease - Maturity of Operating Lease Liability (Details) 2021 Accrued research and other professional fees Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees and accrued research. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). us-gaap_LiabilitiesCurrent Total current liabilities Note 9 - Shareholders' Equity - Shares Reserved (Details) Note 10 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Note 10 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) Warrants Issued in Private Placement [Member] Related to warrants issued in a private placement. Note 11 - Share-based Compensation - Share-based Compensation Expense (Details) Note 11 - Share-based Compensation - Stock Option Activity (Details) Note 11 - Share-based Compensation - Stock Options Outstanding (Details) Commercial Paper and Corporate Bonds [Member] Commercial Papers are unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents and commercial bonds are debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment. Notes To Financial Statements Notes To Financial Statements [Abstract] Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block] Tabular disclosure of marketable securities measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Stock Options Outstanding [Member] Related to stock options outstanding. Common Stock Reserved for Future Issuance [Table Text Block] A tabular disclosure of common stock reserved for future issuance. Share-based Payment Arrangement, Option, Activity [Table Text Block] dmac_ProceedsFromIssuanceOfCommonStockNet Proceeds from Issuance of Common Stock, Net The cash inflow from the issuance of common stock, net of offering costs. The 2012 DSU Plan [Member] Related to the 2012 DSU plan. Exercise Price Range 1 [Member] Related to the first exercise price range. Nonemployee Stock Options [Member] Related to the nonemployee stock options. Exercise Price Range 5 [Member] Related to the fifth exercise price range. Depreciation Exercise Price Range 4 [Member] Related to the fourth exercise price range. US Government Agencies Debt Securities [Member] Maturities of marketable securities Exercise Price Range 3 [Member] Related to the third exercise price range. Exercise Price Range 2 [Member] Related to the second exercise price range. Other comprehensive income (loss) us-gaap_SharesIssuedPricePerShare Shares Issued, Price Per Share (in dollars per share) us-gaap_AssetsCurrent Total current assets Non-current assets: Stockholders' Equity Note Disclosure [Text Block] Exercised, aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue Balance, aggregate intrinsic value Balance, aggregate intrinsic value Sales-based taxes receivable us-gaap_PaymentsToAcquireMarketableSecurities Purchase of marketable securities Common shares, no par value; unlimited authorized; 18,786,157 and 18,746,157 shares issued and outstanding, as of March 31, 2021 and December 31, 2020, respectively Financial Instruments [Domain] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Balance, weighted average exercise price (in dollars per share) Balance, weighted average exercise price (in dollars per share) Measurement Frequency [Domain] Fair Value, Recurring [Member] Common shares, authorized us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent Total accrued liabilities Forfeited, weighted average exercise price (in dollars per share) Common shares, issued (in shares) Expired / cancelled, weighted average exercise price (in dollars per share) us-gaap_LesseeOperatingLeaseDiscountRate Lessee, Operating Lease, Discount Rate Financial Instrument [Axis] Common shares, par value (in dollars per share) Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) Accrued liabilities Accrued compensation Common stock reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance (in shares) Statistical Measurement [Domain] Maximum [Member] Lessee, Operating Leases [Text Block] Minimum [Member] Accounts payable Common Share Purchase Warrants [Member] Common share purchase warrants us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares) Balance (in shares) Balance (in shares) Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Statistical Measurement [Axis] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Expired/cancelled (in shares) Proceeds from disposition of property and equipment us-gaap_PolicyTextBlockAbstract Accounting Policies Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchases of property and equipment Fair Value Hierarchy and NAV [Domain] us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares) Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Fair Value Hierarchy and NAV [Axis] Current liabilities: us-gaap_Assets Total assets Plan Name [Axis] Plan Name [Domain] Cash flows from operating activities: Statement [Line Items] Amounts receivable Total amounts receivable Furniture and Fixtures [Member] us-gaap_CashCashEquivalentsAndShortTermInvestments Cash, Cash Equivalents, and Short-term Investments, Total Paid-in capital Share-based Payment Arrangement [Text Block] Marketable securities Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] AOCI Attributable to Parent [Member] Shareholders’ equity: us-gaap_OtherNonoperatingIncomeExpense Other (income) expense, net Long-Lived Tangible Asset [Axis] us-gaap_NonoperatingIncomeExpense Total other (income) expense Long-Lived Tangible Asset [Domain] Business Description and Basis of Presentation [Text Block] Award Type [Domain] Current assets: Net loss Net loss Net Income (Loss) Attributable to Parent, Total Net loss Award Type [Axis] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium Amortization of discount on marketable securities us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities Sale of Stock [Axis] Sale of Stock [Domain] us-gaap_OperatingIncomeLoss Operating loss us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities, Total Net cash used in operating activities Share-based Payment Arrangement, Option [Member] Other (income) expense: us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Warrant [Member] Prepaid expenses and other assets Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Less accumulated depreciation Property and equipment, net Property and equipment, net Property, plant and equipment, gross Marketable Securities, Policy [Policy Text Block] Concentration Risk, Credit Risk, Policy [Policy Text Block] The 2019 Omnibus Incentive Plan [Member] Represents information related to the 2019 Omnibus Incentive Plan. Stock Option Prior Plan [Member] Information related to the company's stock option plan known as the Prior Plan. The 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan [Member] Information related to the following plans: the 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan. Accrued Interest Receivable On Available For Sale Securities [Member] Represents information related to accrued interest receivable on available for sale securities. us-gaap_MarketableSecurities Marketable Securities, Total Operating expenses: Cash flows from investing activities: Total marketable securities Retained Earnings [Member] Earnings Per Share [Text Block] Proceeds from the exercise of stock options Proceeds from issuance of common shares, net of offering costs Proceeds from Issuance of Common Stock us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Vice President [Member] Additional Paid-in Capital [Member] Common Stock [Member] Related Party Transactions Disclosure [Text Block] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Loss before income tax expense Income tax expense us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued liabilities Bank Certificates of Deposit [Member] Represents information related to bank certificates of deposit. Equity Components [Axis] Equity Component [Domain] us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] General and administrative Cash and cash equivalents Total share-based compensation Computer Equipment [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Amendment Flag General and Administrative Expense [Member] Accounting Policies [Abstract] EX-101.PRE 11 dmac-20210331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 12 dmt01.jpg begin 644 dmt01.jpg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end XML 13 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2021	May 03, 2021
Document Information [Line Items]
Entity Registrant Name	DiaMedica Therapeutics Inc.
Entity Central Index Key	0001401040
Trading Symbol	dmac
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		18,786,157
Entity Shell Company	false
Document Type	10-Q
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q1
Amendment Flag	false
Title of 12(b) Security	Voting common shares, no par value per share

XML 14 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 3,329	$ 7,409
Marketable securities	20,072	20,098
Amounts receivable	337	340
Prepaid expenses and other assets	457	74
Total current assets	24,195	27,921
Non-current assets:
Operating lease right-of-use asset	86	100
Property and equipment, net	75	74
Total non-current assets	161	174
Total assets	24,356	28,095
Current liabilities:
Accounts payable	689	1,099
Accrued liabilities	420	864
Finance lease obligation	6	6
Operating lease obligation	63	59
Total current liabilities	1,178	2,028
Non-current liabilities:
Finance lease obligation, non-current	5	7
Operating lease obligation, non-current	28	46
Total non-current liabilities	33	53
Shareholders’ equity:
Common shares, no par value; unlimited authorized; 18,786,157 and 18,746,157 shares issued and outstanding, as of March 31, 2021 and December 31, 2020, respectively
Paid-in capital	95,680	94,925
Accumulated other comprehensive loss	(4)	(2)
Accumulated deficit	(72,531)	(68,909)
Total shareholders’ equity	23,145	26,014
Total liabilities and shareholders’ equity	$ 24,356	$ 28,095

XML 15 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares $ / shares in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2021	Dec. 31, 2020
Common shares, par value (in dollars per share)	$ 0	$ 0
Common shares, authorized	Unlimited	Unlimited
Common shares, issued (in shares)	18,786,157	18,746,157
Common shares, outstanding (in shares)	18,786,157	18,746,157

XML 16 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Operating expenses:
Research and development	$ 2,406	$ 1,349
General and administrative	1,213	1,055
Operating loss	(3,619)	(2,404)
Other (income) expense:
Governmental assistance - research incentives		(115)
Other (income) expense, net	(4)	127
Total other (income) expense	(4)	12
Loss before income tax expense	(3,615)	(2,416)
Income tax expense	7	9
Net loss	(3,622)	(2,425)
Other comprehensive income (loss)
Unrealized gain (loss) on marketable securities	(2)	40
Net loss and comprehensive loss	$ (3,624)	$ (2,385)
Basic and diluted net loss per share (in dollars per share)	$ (0.19)	$ (0.19)
Weighted average shares outstanding – basic and diluted (in shares)	18,766,656	13,107,725

XML 17 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2019	12,006,874
Balance at Dec. 31, 2019		$ 64,232,000	$ 2,000	$ (56,617,000)	$ 7,617,000
Exercise of common stock options (in shares)	7,200				7,200
Exercise of common stock options		16,000			$ 16,000
Share-based compensation expense		393,000			393,000
Unrealized gain (loss) on marketable securities			40,000		40,000
Net loss				(2,425,000)	(2,425,000)
Issuance of common shares net of offering costs (in shares)	2,125,000
Issuance of common shares net of offering costs		7,682,000			7,682,000
Balance (in shares) at Mar. 31, 2020	14,139,074
Balance at Mar. 31, 2020		73,323,000	42,000	(59,042,000)	13,323,000
Balance (in shares) at Dec. 31, 2020	18,746,157
Balance at Dec. 31, 2020		94,925,000	(2,000)	(68,909,000)	$ 26,014,000
Exercise of common stock options (in shares)	40,000				40,000
Exercise of common stock options		244,000			$ 244,000
Share-based compensation expense		511,000			511,000
Unrealized gain (loss) on marketable securities			(2,000)		(2,000)
Net loss				(3,622,000)	(3,622,000)
Balance (in shares) at Mar. 31, 2021	18,786,157
Balance at Mar. 31, 2021		$ 95,680,000	$ (4,000)	$ (72,531,000)	$ 23,145,000

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References + Details

XML 18 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($)
Stock Issuance [Member]
Offering costs	$ 819

XML 19 R7.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net loss	$ (3,622,000)	$ (2,425,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	511,000	393,000
Amortization of discount on marketable securities	26,000	(14,000)
Non-cash lease expense	14,000	13,000
Depreciation	6,000	6,000
Changes in operating assets and liabilities:
Amounts receivable	3,000	(162,000)
Prepaid expenses and other assets	(383,000)	(397,000)
Accounts payable	(410,000)	262,000
Accrued liabilities	(458,000)	(654,000)
Net cash used in operating activities	(4,313,000)	(2,978,000)
Cash flows from investing activities:
Purchase of marketable securities	(11,923,000)	(8,799,000)
Maturities of marketable securities	11,921,000	3,500,000
Purchases of property and equipment	(9,000)	(2,000)
Proceeds from disposition of property and equipment	2,000
Net cash used in investing activities	(9,000)	(5,301,000)
Cash flows from financing activities:
Proceeds from issuance of common shares, net of offering costs		7,682,000
Proceeds from the exercise of stock options	244,000	16,000
Principal payments on finance lease obligations	(2,000)	(2,000)
Net cash provided by financing activities	242,000	7,696,000
Net decrease in cash and cash equivalents	(4,080,000)	(583,000)
Cash and cash equivalents at beginning of period	7,409,000	3,883,000
Cash and cash equivalents at end of period	$ 3,329,000	$ 3,300,000

XML 20 R8.htm IDEA: XBRL DOCUMENT

Note 1 - Business

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Business Description and Basis of Presentation [Text Block]

Business

199,

a proprietary recombinant human tissue kallikrein-

(

KLK1

) protein for the treatment of acute ischemic stroke (AIS) and chronic kidney disease (CKD). Our parent company is governed under the British Columbia Business Corporations Act, and our common shares are publicly traded on The Nasdaq Capital Market under the symbol “DMAC.”

XML 21 R9.htm IDEA: XBRL DOCUMENT

Note 2 - Risks and Uncertainties

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Risks and Uncertainties [Text Block]

2.	Risks and Uncertainties

DM199,

for the treatment of AIS and CKD. The Company has

not

completed the development of any product candidate and, accordingly, has

not

begun to commercialize any product candidate or generate any revenues from the commercial sale of any product candidate.

DM199

requires significant additional clinical testing and investment prior to seeking marketing approval and is

not

expected to be commercially available for at least

three

five

years, if at all. The Company's future success is dependent upon the success of its development efforts, its ability to demonstrate clinical progress for its

DM199

product candidate in the United States or other markets, its ability to obtain required governmental approvals of its product candidate, its ability to license or market and sell its

DM199

product candidate and its ability to obtain additional financing to fund these efforts.

As of

March 31, 2021,

we have incurred losses of

$72.5

million since our inception in

2000.

For the

three

months ended

March 31, 2021,

we incurred a net loss of

$3.6

million and negative cash flows from operating activities of

$4.3

million. We expect to continue to incur operating losses until such time as any future product sales, royalty payments, licensing fees, and/or milestone payments generate revenue sufficient to fund our continuing operations. For the foreseeable future, we expect to incur significant operating losses as we continue the development and clinical trials of, and to seek regulatory approval for, our

DM199

product candidate. As of

March 31, 2021,

DiaMedica had cash and cash equivalents of

$3.3

million, marketable securities of

$20.1

million, working capital of

$23.0

million and shareholders' equity of

$23.1

million. Our principal source of cash has been net proceeds from the issuance of equity securities. Although the Company has previously been successful in obtaining financing through equity securities offerings, there is

assurance that we will be able to do so in the future. This is particularly true if our clinical data is

not

positive or economic and market conditions deteriorate.

DM199,

or any future product candidates, to a point where they

may

be commercially sold. We expect our current cash, cash equivalents and marketable securities, to be sufficient to allow us to complete our currently ongoing Phase

study in patients with CKD and to otherwise fund our planned operations for at least the next

twelve

months from the date of issuance of these financial statements. However, the amount and timing of our future funding requirements will depend on many factors, including the timing and results of ongoing development efforts, the potential expansion of current development programs, potential new development programs and related general and administrative support. We

may

require significant additional funds earlier than we currently expect and there is

assurance that we will

not

need or seek additional funding prior to such time, especially if market conditions for raising capital are favorable.

XML 22 R10.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Significant Accounting Policies [Text Block]

3.	Summary of Significant Accounting Policies

Interim financial statements

-Q and Regulation S-

of the Securities and Exchange Commission (SEC). Accordingly, they do

not

include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations, consolidated statement of shareholders' equity and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on

December 31.

The condensed consolidated balance sheet as of

December 31, 2020

was derived from our audited consolidated financial statements. Certain prior year amounts have been reclassified to conform to the current year presentation. These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period

may

not

be indicative of the results to be expected for the entire year.

Cash and cash equivalents

The Company considers all bank deposits, including money market funds, and other investments, purchased with an original maturity to the Company of

three

months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.

Concentration of credit risk

one

financial institution. These balances generally exceed federally insured limits. The Company has

not

experienced any losses in such accounts and believes it is

not

exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.

Marketable securities

The Company's marketable securities typically consist of obligations of the United States government and its agencies, investment grade corporate obligations and bank certificates of deposit, which are classified as available-for-sale and included in current assets as they are intended to fund current operations. Securities are valued based on market prices for similar assets using

third

party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of shareholders' equity in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method and are included in other income in the condensed consolidated statements of operations.

Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that

may

indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than

not

be forced to sell the security before recovering its cost, or (iii) does

not

expect to recover the security's amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of shareholders' equity in accumulated other comprehensive income (loss). There were

other-than-temporary unrealized losses as of

March 31, 2021.

Fair value measurements

Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.

The hierarchy is broken down into

three

levels defined as follows:

Level

Inputs

— quoted prices in active markets for identical assets and liabilities

Level

Inputs

— observable inputs other than quoted prices in active markets for identical assets and liabilities

Level

Inputs

— unobservable inputs

As of

March 31, 2021,

the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note

titled “

Marketable Securities

” for additional information.

Patent costs

$48,000

and

$32,000

for the

three

months ended

March 31, 2021

and

2020,

respectively.

XML 23 R11.htm IDEA: XBRL DOCUMENT

Note 4 - Marketable Securities

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

4.	Marketable Securities

	Fair Value Measurements Using Inputs Considered as of:
	March 31, 2021								December 31, 2020
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Government securities	$	6,004	$	—	$	6,004	$	—	$	8,924	$	—	$	8,924	$	—
Bank certificates of deposit		245		—		245		—		496		—		496		—
Commercial paper and corporate bonds		13,823		—		13,823		—		10,678		—		10,678		—
Total	$	20,072	$	—	$	20,072	$	—	$	20,098	$	—	$	20,098	$	—

Accrued interest receivable on available-for-sale securities is included in amounts receivable and was

$37,000

and

$34,000

as of

March 31, 2021

and

December 31, 2020,

respectively.

There were

transfers of assets between Level

and Level

of the fair value measurement hierarchy during the

three

months ended

March 31, 2021.

Under the terms of the Company's investment policy, purchases of marketable securities are limited to investment grade governmental and corporate obligations and bank certificates of deposit with a primary objective of principal preservation. Maturities of individual securities are less than

one

year and the amortized cost of all securities approximated fair value as of

March 31, 2021

and

December 31, 2020.

XML 24 R12.htm IDEA: XBRL DOCUMENT

Note 5 - Amounts Receivable

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Loans, Notes, Trade and Other Receivables Disclosure [Text Block]

5.	Amounts Receivable

Amounts receivable consisted of the following (in thousands):

	March 31, 2021		December 31, 2020
Research and development incentives	$	289	$	289
Sales-based taxes receivable		4		2
Other		44		49
Total amounts receivable	$	337	$	340

XML 25 R13.htm IDEA: XBRL DOCUMENT

Note 6 - Property and Equipment

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Property, Plant and Equipment Disclosure [Text Block]

6.	Property and Equipment

Property and equipment consisted of the following (in thousands):

	March 31, 2021			December 31, 2020
Furniture and equipment	$	61		$	69
Computer equipment		62			62
		123			131
Less accumulated depreciation		(48	)		(57	)
Property and equipment, net	$	75		$	74

XML 26 R14.htm IDEA: XBRL DOCUMENT

Note 7 - Accrued Liabilities

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

7.	Accrued Liabilities

Accrued liabilities consisted of the following (in thousands):

	March 31, 2021		December 31, 2020
Accrued clinical study costs	$	237	$	13
Accrued research and other professional fees		143		360
Accrued compensation		33		483
Accrued taxes and other liabilities		7		8
Total accrued liabilities	$	420	$	864

XML 27 R15.htm IDEA: XBRL DOCUMENT

Note 8 - Operating Lease

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Lessee, Operating Leases [Text Block]

8.	Operating Lease

We lease certain office space under a non-cancelable operating lease. This lease does

not

have significant rent escalation holidays, concessions, leasehold improvement incentives or other build-out clauses. Further this lease does

not

contain contingent rent provisions. This lease terminates on

August 31, 2022

and we do

not

have an option to renew. This lease does include both lease (e.g., fixed rent) and non-lease components (e.g., common-area and other maintenance costs). The non-lease components are deemed to be executory costs and are therefore excluded from the minimum lease payments used to determine the present value of the operating lease obligation and related right-of-use asset.

This lease does

not

provide an implicit rate and, due to the lack of a commercially salable product, we are generally considered unable to obtain commercial credit. Therefore, we estimated our incremental borrowing rate to be

9%,

considering the quoted rates for the lowest investment-grade debt and the interest rates implicit in recent financing leases. We used our estimated incremental borrowing rate and other information available at the lease commencement date in determining the present value of the lease payments.

Our operating lease cost and variable lease costs were

$17,000

and

$14,000,

respectively, for the

three

months ended

March 31, 2021.

Variable lease costs consist primarily of common area maintenance costs, insurance and taxes which are paid based upon actual costs incurred by the lessor.

Maturities of our operating lease obligation are as follows as of

March 31, 2021 (

in thousands):

2021		51
2022		46
Total lease payments	$	97
Less interest portion		(6	)
Present value of lease obligation	$	91

XML 28 R16.htm IDEA: XBRL DOCUMENT

Note 9 - Shareholders' Equity

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Stockholders' Equity Note Disclosure [Text Block]

9.	Shareholders ' Equity

Authorized capital stock

The Company has authorized share capital of an unlimited number of voting common shares and the shares do

not

have a stated par value.

Common shareholders are entitled to receive dividends as declared by the Company, if any, and are entitled to

one

vote per share at the Company's annual general meeting and any special meeting.

Equity issued during the

three

months ended

March 31, 2021

During the

three

months ended

March 31, 2021,

40,000

common shares were issued on the exercise of options for gross proceeds of

$244,000

and

warrants were exercised.

Equity issued during the

three

months ended

March 31, 2020

February 13, 2020,

we issued and sold an aggregate of

2,125,000

common shares in a public, underwritten offering at a public offering price of

$4.00

per share. As a result of the offering, we received gross proceeds of

$8.5

million, which resulted in net proceeds to us of approximately

$7.7

million, after deducting the underwriting discount and offering expenses.

During the

three

months ended

March 31, 2020,

7,200

common shares were issued on the exercise of options for gross proceeds of

$16,000

and

warrants were exercised.

Shares reserved

Common shares reserved for future issuance are as follows:

	March 31, 2021
Stock options outstanding		1,421,094
Deferred share units outstanding		72,142
Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan		1,050,026
Common shares issuable under common share purchase warrants		265,000
Total		2,808,262

XML 29 R17.htm IDEA: XBRL DOCUMENT

Note 10 - Net Loss Per Share

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Earnings Per Share [Text Block]

10.	Net Loss Per Share

The following table summarizes our calculation of net loss per common share for the periods (in thousands, except share and per share data):

	Three Months Ended March 31,
	2021			2020
Net loss	$	(3,622	)	$	(2,425	)
Weighted average shares outstanding—basic and diluted		18,766,656			13,107,725
Basic and diluted net loss per share	$	(0.19	)	$	(0.19	)

The following outstanding potential common shares were

not

included in the diluted net loss per share calculations as their effects were

not

dilutive:

	Three Months Ended March 31,
	2021		2020
Employee and non-employee stock options		1,421,094		1,181,309
Common shares issuable under common share purchase warrants		265,000		255,000
Common shares issuable under deferred unit awards		72,142		21,183

XML 30 R18.htm IDEA: XBRL DOCUMENT

Note 11 - Share-based Compensation

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

Share-based Payment Arrangement [Text Block]

11.	Share-Based Compensation

2019

Omnibus Incentive Plan

The DiaMedica Therapeutics Inc.

2019

Omnibus Incentive Plan (

2019

Plan) was adopted by the Board of Directors in

March 2019

and approved by our shareholders at our annual general and special meeting of shareholders held on

May 22, 2019.

The

2019

Plan permits the Board, or a committee or subcommittee thereof, to grant to the Company's eligible employees, non-employee directors and consultants non-statutory and incentive stock options, stock appreciation rights, restricted stock awards, restricted stock units, deferred stock units, performance awards, non-employee director awards and other stock-based awards. We grant options to purchase common shares under the

2019

Plan at

less than the fair market value of the underlying common shares as of the date of grant. Options granted to employees and non-employee directors have a maximum term of

ten

years and generally vest in approximately equal quarterly installments over

one

three

years. Options granted to non-employees have a maximum term of

five

years and generally vest in approximately equal quarterly installments over

one

year. Subject to adjustment as provided in the

2019

Plan, the maximum number of the Company's common shares authorized for issuance under the

2019

Plan is

2,000,000

shares. As of

March 31, 2021,

options to purchase

930,684

common shares were outstanding and

50,959

common shares were reserved for issuance upon settlement of deferred share units (DSUs) under the

2019

Plan.

Prior stock option plan

The DiaMedica Therapeutics Inc. Stock Option Plan, Amended and Restated

November 6, 2018 (

Prior Plan), was terminated by the Board of Directors in conjunction with the shareholder approval of the

2019

Plan. Awards outstanding under the Prior Plan remain outstanding in accordance with and pursuant to the terms thereof. Options granted under the Prior Plan have terms similar to those used under the

2019

Plan. As of

March 31, 2021,

options to purchase

490,410

common shares were outstanding under the Prior Plan.

As the TSX Venture Exchange was the principal trading market for the Company's common shares, all options granted prior to

December 31, 2018

were priced in Canadian dollars. Options granted after

December 31, 2018

have been priced in United States dollars.

Prior deferred share unit plan

The DiaMedica Therapeutics Inc. Amended and Restated Deferred Share Unit Plan (DSU Plan) was terminated by the Board of Directors in conjunction with the shareholder approval of the

2019

Plan. Awards outstanding under the DSU Plan remain outstanding in accordance with and pursuant to the terms thereof. As of

March 31, 2021,

there were

21,183

common shares reserved for DSUs outstanding.

The aggregate number of common shares reserved for issuance for awards granted under the

2019

Plan, the Prior Plan and the DSU Plan as of

March 31, 2021

was

1,493,234.

Share-based compensation expense for each of the periods presented is as follows (in thousands):

	Three Months Ended March 31
	2021		2020
Research and development	$	131	$	107
General and administrative		380		286
Total share-based compensation	$	511	$	393

A summary of option activity is as follows (in thousands except share and per share amounts):

	Shares Underlying Options Outstanding			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balances at December 31, 2020		1,389,568		$	5.38	$	7,109
Granted		85,000			9.69
Exercised		(40,000	)		6.11		132
Expired/cancelled		(13,474	)		6.54
Forfeited		—			—
Balances at March 31, 2021		1,421,094		$	5.60	$	5,589

Information about stock options outstanding, vested and expected to vest as of

March 31, 2021,

is as follows:

			Outstanding, Vested and Expected to Vest						Options Vested and Exercisable
Per Share Exercise Price			Shares		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life (Years)
$2.00	-	$2.99		120,500		4.7	$	2.41		120,500		4.7
$3.00	-	$3.99		17,500		6.0		3.84		17,500		6.0
$4.00	-	$4.99		938,567		8.2		4.51		680,974		7.9
$5.00	-	$9.99		274,527		7.4		8.03		198,216		6.7
$10.00	-	$27.06		70,000		4.0		16.62		50,000		1.6
				1,421,094		7.5	$	5.60		1,067,190		7.0

XML 31 R19.htm IDEA: XBRL DOCUMENT

Note 12 - Related Party Transaction

3 Months Ended

Mar. 31, 2021

Notes to Financial Statements

12.	Related Party Transaction

During

2021,

we have engaged a consulting firm owned by our Vice President of Regulatory Affairs to perform certain tasks supporting our quality and regulatory activities. The work is performed as required by us and all services are invoiced on an hourly basis with

minimum commitment. Total charges invoiced were approximately

$107,000

during the

three

-months ended

March 31, 2021,

and are recorded as research and development expenses, of which approximately

$52,000

was outstanding and included in accounts payable as of

March 31, 2021.

XML 32 R20.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)	3 Months Ended
Significant Accounting Policies (Policies)	Mar. 31, 2021
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Interim financial statements We have prepared the accompanying condensed consolidated financial statements in accordance with accounting principles generally accepted in the United States (US GAAP) for interim financial information and with the instructions to Form 10 -Q and Regulation S- X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by US GAAP for complete financial statements. These condensed consolidated financial statements reflect all adjustments consisting of normal recurring accruals which, in the opinion of management, are necessary to present fairly our consolidated financial position, consolidated results of operations, consolidated statement of shareholders' equity and consolidated cash flows for the periods and as of the dates presented. Our fiscal year ends on December 31. The condensed consolidated balance sheet as of December 31, 2020 was derived from our audited consolidated financial statements. Certain prior year amounts have been reclassified to conform to the current year presentation. These condensed consolidated financial statements should be read in conjunction with our annual consolidated financial statements and the notes thereto. The nature of our business is such that the results of any interim period may not be indicative of the results to be expected for the entire year.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and cash equivalents The Company considers all bank deposits, including money market funds, and other investments, purchased with an original maturity to the Company of three months or less, to be cash and cash equivalents. The carrying amount of our cash equivalents approximates fair value due to the short maturity of the investments.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of credit risk Financial instruments that potentially expose the Company to concentration of credit risk consist primarily of cash, cash equivalents and marketable securities. The Company maintains its cash balances primarily with one financial institution. These balances generally exceed federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk in cash and cash equivalents. The Company believes that the credit risk related to marketable securities is limited due to the adherence to an investment policy focused on the preservation of principal.
Marketable Securities, Policy [Policy Text Block]	Marketable securities The Company's marketable securities typically consist of obligations of the United States government and its agencies, investment grade corporate obligations and bank certificates of deposit, which are classified as available-for-sale and included in current assets as they are intended to fund current operations. Securities are valued based on market prices for similar assets using third party certified pricing sources. Available-for-sale securities are carried at fair value with unrealized gains and losses reported as a component of shareholders' equity in accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization or accretion is included in interest income. Realized gains and losses, if any, are calculated on the specific identification method and are included in other income in the condensed consolidated statements of operations. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security's amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of shareholders' equity in accumulated other comprehensive income (loss). There were no other-than-temporary unrealized losses as of March 31, 2021.
Fair Value Measurement, Policy [Policy Text Block]	Fair value measurements Under the authoritative guidance for fair value measurements, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The authoritative guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company's assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. The categorization of financial assets and financial liabilities within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is broken down into three levels defined as follows: Level 1 Inputs — quoted prices in active markets for identical assets and liabilities Level 2 Inputs — observable inputs other than quoted prices in active markets for identical assets and liabilities Level 3 Inputs — unobservable inputs As of March 31, 2021, the Company believes that the carrying amounts of its other financial instruments, including amounts receivable, accounts payable and accrued liabilities, approximate their fair value due to the short-term maturities of these instruments. See Note 4, titled “ Marketable Securities ” for additional information.
Patent Costs [Policy Text Block]	Patent costs Costs associated with applying for, prosecuting and maintaining patents are expensed as incurred given the uncertainty of patent approval and, if approved, the resulting probable future economic benefit to the Company. Patent-related costs, consisting primarily of legal expenses and filing/maintenance fees, are included in general and administrative costs and were $48,000 and $32,000 for the three months ended March 31, 2021 and 2020, respectively.

XML 33 R21.htm IDEA: XBRL DOCUMENT

Note 4 - Marketable Securities (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Fair Value, Marketable Securities Measured on a Recurring Basis [Table Text Block]

	Fair Value Measurements Using Inputs Considered as of:
	March 31, 2021								December 31, 2020
	Total		Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3
Government securities	$	6,004	$	—	$	6,004	$	—	$	8,924	$	—	$	8,924	$	—
Bank certificates of deposit		245		—		245		—		496		—		496		—
Commercial paper and corporate bonds		13,823		—		13,823		—		10,678		—		10,678		—
Total	$	20,072	$	—	$	20,072	$	—	$	20,098	$	—	$	20,098	$	—

XML 34 R22.htm IDEA: XBRL DOCUMENT

Note 5 - Amounts Receivable (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]

	March 31, 2021		December 31, 2020
Research and development incentives	$	289	$	289
Sales-based taxes receivable		4		2
Other		44		49
Total amounts receivable	$	337	$	340

XML 35 R23.htm IDEA: XBRL DOCUMENT

Note 6 - Property and Equipment (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Property, Plant and Equipment [Table Text Block]

	March 31, 2021			December 31, 2020
Furniture and equipment	$	61		$	69
Computer equipment		62			62
		123			131
Less accumulated depreciation		(48	)		(57	)
Property and equipment, net	$	75		$	74

XML 36 R24.htm IDEA: XBRL DOCUMENT

Note 7 - Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Schedule of Accrued Liabilities [Table Text Block]

	March 31, 2021		December 31, 2020
Accrued clinical study costs	$	237	$	13
Accrued research and other professional fees		143		360
Accrued compensation		33		483
Accrued taxes and other liabilities		7		8
Total accrued liabilities	$	420	$	864

XML 37 R25.htm IDEA: XBRL DOCUMENT

Note 8 - Operating Lease (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

2021		51
2022		46
Total lease payments	$	97
Less interest portion		(6	)
Present value of lease obligation	$	91

XML 38 R26.htm IDEA: XBRL DOCUMENT

Note 9 - Shareholders' Equity (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Common Stock Reserved for Future Issuance [Table Text Block]

	March 31, 2021
Stock options outstanding		1,421,094
Deferred share units outstanding		72,142
Shares available for grant under the DiaMedica Therapeutics Inc. Omnibus Incentive Plan		1,050,026
Common shares issuable under common share purchase warrants		265,000
Total		2,808,262

XML 39 R27.htm IDEA: XBRL DOCUMENT

Note 10 - Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended March 31,
	2021			2020
Net loss	$	(3,622	)	$	(2,425	)
Weighted average shares outstanding—basic and diluted		18,766,656			13,107,725
Basic and diluted net loss per share	$	(0.19	)	$	(0.19	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Three Months Ended March 31,
	2021		2020
Employee and non-employee stock options		1,421,094		1,181,309
Common shares issuable under common share purchase warrants		265,000		255,000
Common shares issuable under deferred unit awards		72,142		21,183

XML 40 R28.htm IDEA: XBRL DOCUMENT

Note 11 - Share-based Compensation (Tables)

3 Months Ended

Mar. 31, 2021

Notes Tables

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended March 31
	2021		2020
Research and development	$	131	$	107
General and administrative		380		286
Total share-based compensation	$	511	$	393

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Shares Underlying Options Outstanding			Weighted Average Exercise Price Per Share		Aggregate Intrinsic Value
Balances at December 31, 2020		1,389,568		$	5.38	$	7,109
Granted		85,000			9.69
Exercised		(40,000	)		6.11		132
Expired/cancelled		(13,474	)		6.54
Forfeited		—			—
Balances at March 31, 2021		1,421,094		$	5.60	$	5,589

Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]

			Outstanding, Vested and Expected to Vest						Options Vested and Exercisable
Per Share Exercise Price			Shares		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Options Exercisable		Weighted Average Remaining Contractual Life (Years)
$2.00	-	$2.99		120,500		4.7	$	2.41		120,500		4.7
$3.00	-	$3.99		17,500		6.0		3.84		17,500		6.0
$4.00	-	$4.99		938,567		8.2		4.51		680,974		7.9
$5.00	-	$9.99		274,527		7.4		8.03		198,216		6.7
$10.00	-	$27.06		70,000		4.0		16.62		50,000		1.6
				1,421,094		7.5	$	5.60		1,067,190		7.0

XML 41 R29.htm IDEA: XBRL DOCUMENT

Note 2 - Risks and Uncertainties (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020	Dec. 31, 2019
Retained Earnings (Accumulated Deficit), Ending Balance	$ (72,531)		$ (68,909)
Net Income (Loss) Attributable to Parent, Total	(3,622)	$ (2,425)
Net Cash Provided by (Used in) Operating Activities, Total	(4,313)	(2,978)
Cash, Cash Equivalents, and Short-term Investments, Total	3,300
Marketable Securities, Total	20,100
Working Capital	23,000
Stockholders' Equity Attributable to Parent, Ending Balance	$ 23,145	$ 13,323	$ 26,014	$ 7,617

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

+ References + Details

XML 42 R30.htm IDEA: XBRL DOCUMENT

Note 3 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Research and Development Expense [Member]
Patent Expense	$ 48,000	$ 32,000

XML 43 R31.htm IDEA: XBRL DOCUMENT

Note 4 - Marketable Securities (Details Textual) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Accrued Interest Receivable On Available For Sale Securities [Member]
Interest Receivable	$ 37,000	$ 34,000

XML 44 R32.htm IDEA: XBRL DOCUMENT

Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) - Fair Value, Recurring [Member] - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Total marketable securities	$ 20,072	$ 20,098
Fair Value, Inputs, Level 1 [Member]
Total marketable securities
Fair Value, Inputs, Level 2 [Member]
Total marketable securities	20,072	20,098
Fair Value, Inputs, Level 3 [Member]
Total marketable securities
US Government Agencies Debt Securities [Member]
Total marketable securities	6,004	8,924
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Total marketable securities
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 2 [Member]
Total marketable securities	6,004	8,924
US Government Agencies Debt Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Total marketable securities
Bank Certificates of Deposit [Member]
Total marketable securities	245	496
Bank Certificates of Deposit [Member] \| Fair Value, Inputs, Level 1 [Member]
Total marketable securities
Bank Certificates of Deposit [Member] \| Fair Value, Inputs, Level 2 [Member]
Total marketable securities	245	496
Bank Certificates of Deposit [Member] \| Fair Value, Inputs, Level 3 [Member]
Total marketable securities
Commercial Paper and Corporate Bonds [Member]
Total marketable securities	13,823	10,678
Commercial Paper and Corporate Bonds [Member] \| Fair Value, Inputs, Level 1 [Member]
Total marketable securities
Commercial Paper and Corporate Bonds [Member] \| Fair Value, Inputs, Level 2 [Member]
Total marketable securities	13,823	10,678
Commercial Paper and Corporate Bonds [Member] \| Fair Value, Inputs, Level 3 [Member]
Total marketable securities

XML 45 R33.htm IDEA: XBRL DOCUMENT

Note 5 - Amounts Receivable - Amounts Receivable (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Research and development incentives	$ 289	$ 289
Sales-based taxes receivable	4	2
Other	44	49
Total amounts receivable	$ 337	$ 340

XML 46 R34.htm IDEA: XBRL DOCUMENT

Note 6 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Property, plant and equipment, gross	$ 123	$ 131
Less accumulated depreciation	(48)	(57)
Property and equipment, net	75	74
Furniture and Fixtures [Member]
Property, plant and equipment, gross	61	69
Computer Equipment [Member]
Property, plant and equipment, gross	$ 62	$ 62

XML 47 R35.htm IDEA: XBRL DOCUMENT

Note 7 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Accrued clinical study costs	$ 237	$ 13
Accrued research and other professional fees	143	360
Accrued compensation	33	483
Accrued taxes and other liabilities	7	8
Total accrued liabilities	$ 420	$ 864

XML 48 R36.htm IDEA: XBRL DOCUMENT

Note 8 - Operating Lease (Details Textual)	3 Months Ended
Note 8 - Operating Lease (Details Textual)	Mar. 31, 2021 USD ($)
Lessee, Operating Lease, Discount Rate	9.00%
Operating Lease, Cost	$ 17,000
Variable Lease, Cost	$ 14,000

XML 49 R37.htm IDEA: XBRL DOCUMENT

Note 8 - Operating Lease - Maturity of Operating Lease Liability (Details) $ in Thousands	Mar. 31, 2021 USD ($)
2021	$ 51
2022	46
Total lease payments	97
Less interest portion	(6)
Present value of lease obligation	$ 91

XML 50 R38.htm IDEA: XBRL DOCUMENT

Note 9 - Shareholders' Equity (Details Textual) - USD ($)		3 Months Ended
	Feb. 13, 2020	Mar. 31, 2021	Mar. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)		40,000	7,200
Stock Issued During Period, Value, Stock Options Exercised		$ 244,000	$ 16,000
Stock Issued During Period, Shares, Exercise of Common Stock Warrants (in shares)		0
Stock Issued During Period, Shares, New Issues (in shares)	2,125,000
Shares Issued, Price Per Share (in dollars per share)	$ 4
Proceeds from Issuance of Common Stock	$ 8,500,000		$ 7,682,000
Proceeds from Issuance of Common Stock, Net	$ 7,700,000
Warrants Issued in Private Placement [Member]
Stock Issued During Period, Shares, Exercise of Common Stock Warrants (in shares)			0

XML 51 R39.htm IDEA: XBRL DOCUMENT

Note 9 - Shareholders' Equity - Shares Reserved (Details)	Mar. 31, 2021 shares
Common stock reserved for future issuance (in shares)	2,808,262
Stock Options Outstanding [Member]
Common stock reserved for future issuance (in shares)	1,421,094
Deferred Share Units [Member]
Common stock reserved for future issuance (in shares)	72,142
The 2019 Omnibus Incentive Plan [Member]
Common stock reserved for future issuance (in shares)	1,050,026
Common Share Purchase Warrants [Member]
Common stock reserved for future issuance (in shares)	265,000

XML 52 R40.htm IDEA: XBRL DOCUMENT

Note 10 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Net loss	$ (3,622)	$ (2,425)
Weighted average shares outstanding—basic and diluted (in shares)	18,766,656	13,107,725
Basic and diluted net loss per share (in dollars per share)	$ (0.19)	$ (0.19)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

XML 53 R41.htm IDEA: XBRL DOCUMENT

Note 10 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) - shares	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Employee and Non-employee Stock Options [Member]
Antidilutive Securities (in shares)	1,421,094	1,181,309
Warrant [Member]
Antidilutive Securities (in shares)	265,000	255,000
Deferred Share Units [Member]
Antidilutive Securities (in shares)	72,142	21,183

XML 54 R42.htm IDEA: XBRL DOCUMENT

Note 11 - Share-based Compensation (Details Textual) - shares	1 Months Ended
	Mar. 30, 2019	Mar. 31, 2021
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		2,808,262
The 2019 Omnibus Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)	2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		930,684
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		50,959
The 2019 Omnibus Incentive Plan [Member] \| Employee and Non-employee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
The 2019 Omnibus Incentive Plan [Member] \| Employee and Non-employee Stock Options [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year
The 2019 Omnibus Incentive Plan [Member] \| Employee and Non-employee Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	3 years
The 2019 Omnibus Incentive Plan [Member] \| Nonemployee Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year
Stock Option Prior Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)		490,410
The 2012 DSU Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		21,183
The 2019 Omnibus Incentive Plan, Stock Option Prior Plan, and the 2012 DSU Plan [Member]
Common Stock, Capital Shares Reserved for Future Issuance (in shares)		1,493,234

XML 55 R43.htm IDEA: XBRL DOCUMENT

Note 11 - Share-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Total share-based compensation	$ 511	$ 393
Research and Development Expense [Member]
Total share-based compensation	131	107
General and Administrative Expense [Member]
Total share-based compensation	$ 380	$ 286

XML 56 R44.htm IDEA: XBRL DOCUMENT

Note 11 - Share-based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Exercised (in shares)	(40,000)	(7,200)
Share-based Payment Arrangement, Option [Member]
Balance (in shares)	1,389,568
Balance, weighted average exercise price (in dollars per share)	$ 5.38
Balance, aggregate intrinsic value	$ 7,109
Granted (in shares)	85,000
Granted, weighted average exercise price (in dollars per share)	$ 9.69
Exercised (in shares)	(40,000)
Exercised, weighted average exercise price (in dollars per share)	$ 6.11
Exercised, aggregate intrinsic value	$ 132
Expired/cancelled (in shares)	(13,474)
Expired / cancelled, weighted average exercise price (in dollars per share)	$ 6.54
Forfeited (in shares)
Forfeited, weighted average exercise price (in dollars per share)
Balance (in shares)	1,421,094
Balance, weighted average exercise price (in dollars per share)	$ 5.60
Balance, aggregate intrinsic value	$ 5,589

XML 57 R45.htm IDEA: XBRL DOCUMENT

Note 11 - Share-based Compensation - Stock Options Outstanding (Details)	3 Months Ended
	Mar. 31, 2021 $ / shares shares
Outstanding, shares (in shares) \| shares	1,421,094
Outstanding, weighted average remaining contractual life (Year)	7 years 182 days
Outstanding, weighted average exercise price (in dollars per share)	$ 5.60
Exercisable, shares (in shares) \| shares	1,067,190
Exercisable, weighted average remaining contractual life (Year)	7 years
Exercise Price Range 1 [Member]
Per share exercise price, lower range (in dollars per share)	$ 2
Per share exercise price, upper range (in dollars per share)	$ 2.99
Outstanding, shares (in shares) \| shares	120,500
Outstanding, weighted average remaining contractual life (Year)	4 years 255 days
Outstanding, weighted average exercise price (in dollars per share)	$ 2.41
Exercisable, shares (in shares) \| shares	120,500
Exercisable, weighted average remaining contractual life (Year)	4 years 255 days
Exercise Price Range 2 [Member]
Per share exercise price, lower range (in dollars per share)	$ 3
Per share exercise price, upper range (in dollars per share)	$ 3.99
Outstanding, shares (in shares) \| shares	17,500
Outstanding, weighted average remaining contractual life (Year)	6 years
Outstanding, weighted average exercise price (in dollars per share)	$ 3.84
Exercisable, shares (in shares) \| shares	17,500
Exercisable, weighted average remaining contractual life (Year)	6 years
Exercise Price Range 3 [Member]
Per share exercise price, lower range (in dollars per share)	$ 4
Per share exercise price, upper range (in dollars per share)	$ 4.99
Outstanding, shares (in shares) \| shares	938,567
Outstanding, weighted average remaining contractual life (Year)	8 years 73 days
Outstanding, weighted average exercise price (in dollars per share)	$ 4.51
Exercisable, shares (in shares) \| shares	680,974
Exercisable, weighted average remaining contractual life (Year)	7 years 328 days
Exercise Price Range 4 [Member]
Per share exercise price, lower range (in dollars per share)	$ 5
Per share exercise price, upper range (in dollars per share)	$ 9.99
Outstanding, shares (in shares) \| shares	274,527
Outstanding, weighted average remaining contractual life (Year)	7 years 146 days
Outstanding, weighted average exercise price (in dollars per share)	$ 8.03
Exercisable, shares (in shares) \| shares	198,216
Exercisable, weighted average remaining contractual life (Year)	6 years 255 days
Exercise Price Range 5 [Member]
Per share exercise price, lower range (in dollars per share)	$ 10
Per share exercise price, upper range (in dollars per share)	$ 27.06
Outstanding, shares (in shares) \| shares	70,000
Outstanding, weighted average remaining contractual life (Year)	4 years
Outstanding, weighted average exercise price (in dollars per share)	$ 16.62
Exercisable, shares (in shares) \| shares	50,000
Exercisable, weighted average remaining contractual life (Year)	1 year 219 days

XML 58 R46.htm IDEA: XBRL DOCUMENT

Note 12 - Related Party Transaction (Details Textual) - Vice President [Member] - Consulting Services [Member]	3 Months Ended
	Mar. 31, 2021 USD ($)
Accounts Payable, Related Parties, Current	$ 52,000
Research and Development Expense [Member]
Related Party Transaction, Amounts of Transaction	$ 107,000

EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

!HW MC9ND=QN&84PW)]2'K?KPHOHKTYPM!?Q/?'@L/C@6IP>M6H#._$ :XJ^Y[MIV MMYWYA[K5_Z37#X;MAHQ+0P2L+33LWEH'NA[".D!5^L9?*K1CY)>Y?;= NP1[ MOE:V^9O ";0O8?(;4$L#!!0 ( >$I5)@WBM /0( &T% 9 >&PO M=V]R:W-H965TJ;4@/?.E N_3 ((C_GHO#BJ5M;ZGBJ*I2B M@*5FILISKO=SD*J>>4/O8^%9I!G:!3^>ECR%%>!KN=0T\SN6K1K7<%/P74YF#,;)*U4F]V\FT[\P)K""1LT#)P>NW@ :2T1&3C=\OI M=9(6>#C^8/_BLE.6-3?PH.0OL<5LYMUZ; L)KR0^J_HKM'DFEF^CI'%/5K>U M@<?/W]CL< ,+A"4#8 D+GNQ%R+A<<>3S5JF;:5A.;';BH M#DWF1&$/986:=@7A,/ZN$-@MNV8_2M <19&R1Z"4M/+$L=("]TPE1[N/@J^% MM)N7"T NI+EB%TP4["53E>'%UDQ])'M6Q-^T5N:-E?"$E2>N!VPT_,3"(!R^ MKA;L\N+J;Q:?PG4)PRYAZ&C')V@M6Y^9!A4YE/UU=_&$ZG8]2J-.:?0_I;!/ MJ4%-#I3&4;_2N%,:GU5Z4<@ED^XH2KZG)L'>#SX^4KZ[Z5>>=,J3L\J/8 R= M,X(&@ZQ4VO96G_3D2/KZ1.BHDX[.2B])DH*R'9<5V)^RR:_64J3\E(WHZ)3O M_CUE_Z![[$5$_V$J"D/T"8&"P0V%T$US-Q-4I6NHM4)J3S?,Z#X$;0MH/U'4 M5.W$]FAWP\9_ %!+ P04 " 'A*52LHY^O4\# !/"@ &0 'AL+W=O M>WMCBFO?U\D>,Z8O98$Y?=E*E3%#4[7S=:&0I0Z4"3\*@K&?,9Y[ MBYE;6ZO%3)9&\!S7"G2994P]WJ*0Q[D7>C\7/O'=WM@%?S$KV [OT'PIUHIF M?N,EY1GFFLL<%&[GWDUXO0H#"W 67SD>=6L,5LI&RGL[>9_.O< R0H&)L2X8 M_1QPB4)83\3C>^W4:V):8'O\T_L[)Y[$;)C&I13?>&KV[, ETZ%)/L]MW>^,HJ^<<&;Q41J$*W@# M=WNF<"]%BDJ_@K??2VX>X6*%AG&AX3,^F)*)UV3XY6X%%[^]GOF&PELG?E*' MNJU"12="O%VYD<@_OM2Y)T:I4/-_5G ?PE8D2!U"9U/(:=6F?CBK6N,4PBN.N MD*Y9. Y.*8D;)?$_5N+*UBH-R*TMA(H?&'6GM:!LN7OSSP^8;5#]=>;Z#H._&U_POY_^5TX79L"MX0)+B<$5M7KI9H86;A^OI&&7@=NN*<7'RIK0-^W MDGIZ/;%/A.8-N?@!4$L#!!0 ( >$I5(&PO M=V]R:W-H965T/B^K\4;I!Y,#6/)4 M%M),@MS:ZCP,39)#RQO7R>LJ&=,AB-@[7._2==?K.]NI;>&&SRO6@(;/:&LME*N2*_+Z!<@GZ MSQX3>AU)[S@F]-Z8$/581$>]W2;T.WW]O?JN( .M49)O)W(GA36'U!]W^/%Q MZH_?U#]@Z,#NZ@>=NL%>=3]SP)Z/1F162K&L#;E&)=)-(S(ON#S$B&%'-3R. M$<.WC4#[E+)XMQ6C3M_H$'U-&\QKG>0X4"N!?_H",DRDIP-$T,TMT6RLJOQD7BJ+<]XO<[Q90;L M?)\IG,[MQ@W[[JZ>_@502P,$% @ !X2E4I71&A?! @ JP8 !D !X M;"]W;W)K&ULC55M;]HP$/XKIZR:6JDE;Q!8!TB% M;MJDM4)E73^[B2%6'9O9!KI_O[,=LI0!VQ>PS_>$Y_4)K/8Y@ M+KEVO["M?:, \K4VLJK!R*!BPO^3USH/+0#&.0Q(:D"R#^@> :0U('5"/3,G MZY88,AXJN05EO3&:7;C<.#2J8<)6<6X4GC+$F?&]-!3B"*[@'I_,-ZDUS*B" M>4D41>/<%Q?D N9L*=B"Y408N,ESN1:&B27,)&!3,Z$LTXOI[*=>:B$(/0X,2+=$PK^5,O)SD MB)P4[J0PI89/HJ#%6WR(J6GRD^SR,TE.!KPCJ@-I? E)E,0'^$S_'QZ=H),V MY4I=O.ZQ2ZA19 -E1A\^\*BV-#&ZPD/I3W[P9)G'S$EF,YH D*QM<6J M93VHQU_6;^<_ZL0?]L3\R\LK"5M]7U&U=.-0@^M-_\0;:S-Q;]R@V;-/T'R?QK\!4$L#!!0 ( >$I5+U!&PO=V]R M:W-H965T= %@R$O)A9YX MA3'5I>_KM("2ZG-9@< ON50E-;A5*U]7"FCF0"7WHR 8^"5EPDO&SC97R5C6 MAC,!S;Q BL(.*3&,E#\>X89<&Z)4,;? MEM/K0EK@]GK#_M7ECKDLJ8:9Y(\L,\7$&WDD@YS6W-S+]3=H\^E;OE1R[7[) MNO4-/)+6VLBR!:."DHGFG[ZT==@"(,]A0-0"HGU [QU W )BEVBCS*5U30U- MQDJNB;+>R&87KC8.C=DP84]Q811^98@SR9TT0,* G)$[O#(_I-9D#HHL"JH MC0N\-5G-@T#/[.#PX(B?NCB1V?+UW^&[*BLM7 $)%1NZD.(.-86%D^D1^ M5K; FOR^A7()ZL^1D+TN9.]HR-VCA;16S# \WA,FVF,Z/71.#6G?D=IV\9R$ MO2@,+GIC_WF[?@?\PE$8!Q>=WX[J?J>Z?U3U(U6*"O.10@PZRL%G%&+P)L%H MT ^"8*\.!]SZ.VX[FH>=YN%1S=>0@U+X!ILG]B"8^=#E&'7\H\^HR>A-LL,( MK\=>2=YZ17@WXKV*^%L-K@2U$I5)O1/DW^@, 02 9 >&PO=V]R:W-H965T MH> M#!F(U<3.V4Z!T_WXLYV0T"T$=K6HQP.)'<_,-Y_'^>ST5T(^J0A HW420)< 5 M$QQ)6 P:(_QA3(@U<".^,EBIG7MD4YD)\60;=^&@X5M$$,-<6Q?47)YA#'%L M/1D 2 MS9&YM&ZHIL.^%"LD[6CCS=XX;IRUR89Q.XU3+=AR,'PF%T M+[B.%+KE(80O[3T#O<1/MOBO2:W#>RHO4> W$?%Q;P^>\2GFV)H37 ,G*.D, MG+_6 7^&N,10-M5B_M1$8YHR3>.<6H4>08%\-O2:U8<^9CJ3@.Z4RBB? WK' M>,'J^WUIY&';+JQ=FL]#TO6[I$/ZWO,>O*T2;ZL6[^<(''/H4\+9+%/HSF#A M=F6A24PY^GX/R0SD7S74M,M0[=I0!^MK)"7E2S#O!HUFFQ=U.*$;USU:41DV MT4-FP2"QV#(ZRG0D)/O'#*WG[[K]FC_?_?;SURF3ZIP[J4^I-5#F)M-*4QXR MOMRFVK3KQ+31-8U/J9+.JRQ[@=_IMO8G>54F>?4V17WU"F[;[[5[^]%V2[3= MWU+2Z%]TFZ2QV @PSIZ$/P"MATNU^W4G+(*>B6ZWKD+YG:=,ID;34 R86K_ M&U"YM^SKP6 ?;8REJLD+^Y60^&_%NS&Y9YPE67+*5. =[N%\\WF(YZ0,'QY5$)+?X]2FO(-5/P MZR\B7.DQ/KL@_\RKZ B:]G&N*U'&9U?EGRVD>D#'UW6EQ;A>C'<+ DT,+'GR M3@U7$HKK-?1_MJTIT.YN%%H]OX4/;-YP)<:X7@"+14G0S?3+R3222A))O22> M;>-4Q'VQG<6X&^SG@U2"2.KUY\A+JHD.5%_328?^)38K12/UBG8^-LDK-G&K M%Y#@QWVSMW/.3D NW><'A>8BXSH_]Y2>.D3O8>]7P_/N(.7@NF7FCQ[ P MIO[EE8DN\T\.>4.+U)W:9T)KD;C;"&@(T@XPSQ?"G-R+A@U0?O@9_@=02P,$ M% @ !X2E4L#\81"1 @ #@< !D !X;"]W;W)K&ULK57;3MM $/V5E<4#2 7?3 MT+_O[-JX)H2HE7BQ]S+G[)FSGO%HJ_2C*0$L>1)N&.KTKJ%,!M5= 5SL _5K<99V+(43( T3$FB83D.+N.+Z=#%^X!O M#+:F,R8NDX52CVYR78R#R D"#KEU#!1?&Y@"YXX(9?QJ.(/V2 ?LCI_9/_G< M,9<%-3!5_#LK;#D.S@-2P)*NN;U3VR_0Y--W?+GBQC_)MHF- I*OC56B :," MP63]ID^-#QT \NP') T@V07TW@"D#2#UB=;*?%HS:FDVTFI+M(M&-C?PWG@T M9L.DN\6YU;C+$&>SK\H"B6-R2N8EU7#J+"G(5 G\3 SU3A_8NGIR8R#',["4 M<7."P0_S&3D^.B%'A$ER7ZJUH;(PH]"B6G=FF#?*)K6RY UE*;E1TI:&7,D" MBI?X$+-L4TV>4YTD!PEOJ#XC:?R!)%$2[]$S_7=X=$!.VCJ?>K[>&WSWRE). M3,?:O&/M/K]JOH'G<]6YR?HQ)K+IYO Z)OV8MC$OA/9:H;V#0N_ -5Y2? > MR0PV6/D5UK%M;__'#8@%Z)\'3.FW9_7?V92:K]]).$YW3=D3$PWWFS)HA0X. M"OT,$C1*=9Y<%EB8S%A-74OZ'UN&[6G#=[9E^/H[.(]V;'D=DYP/=FP).ZU% M@%[YCFOP^+6T=>FUJVU3O_2];&=]@LV^[LU_:>H_!1;6BDE#."R1,CH;XD7I MNOO6$ZLJW\ 6RF([],,2?UB@70#N+Q4VL6;B#FA_@=D?4$L#!!0 ( >$ MI5(U-&PO=V]R:W-H965T5WXQM<;;1;<^31C:[@'_9#=29RY)4K$$T@5%RF1L)HYU_1J22=&P.[X MF\->U<;$F/(HQ).9?(UFCF<800RA-A ,?W:PA#@V2,CC1P'JE#J-8'W\BO[% M&H_&/#(%2Q'_PR.]F3ECAT2P8MM8?Q/[WZ$P*#!XH8B5_4_VQ5[/(>%6:9$4 MPL@@X6G^RYX+1]0$$*=9P"\$_+<"@Q:!?B'0MX;FS*Q9-TRS^52*/9%F-Z*9 M@?6-E49K>&K">*\E?N4HI^=_" V$4G))[C=,PJ5Q2426(L%SHICU-'[2(GPB M?V9V>FTTFC_U>B%WPEXRV2/ M].D%\3V?-O!9'B_N==#IES'H6[Q!"][G9Y A-WX_0T?E[CMO!-UN1:2I:NP8PO7H_'O[>0 M/(+\WN&7H%09=*I"=N;0_G@3#<;/!PU+[\!CM%V1O4P&:S78@ M,;41*.)%,LD+>I&(8R85R4#F5!N9Y@I'-:9!K]]"28:$.R8_$6FICDF,,:DQ'U)LU,QB63<2>3W_ PZ(\/\?A=N,:!UW8Z)Z7N MR3&Z3QFLR;M@37K#%A=1KTJWWFGN>H'3<=D/&=02/CV.P2F=5>BL>VO8H[2% MJU]Q]8_E^K^.=P$[/,@)?@N;*DW3C_)TQB5$;F@N7!P?$<.&3$S[@]&@A4F5 MBVEW,BZ88+$MN9PTFH.&: 9MK*MT3KOS.;Z[5L"/2!'=..9E>Z4R%L+,P:>K M KD#9TXZ"@ZM"8/RV2+BUYWD"&ULQ5K;;N,V$/T5 MPNA#%MBUQ(MN"\? )KM%^Y!ND* MBJ(/C$W'0G1Q*3I.@'Y\*8D6Y=JDY%A. M\V#KQCE#SLPY,B>33B5]7MUR>.8V5>9RRK(CS#'"VN!Q]@9^O2% . MJ)[X+6:;HG4,RJD\Y/E3>?+S_'+DEAZQA,U$:8+*KV=VS9*DM"3]^%L9'368 MY<#V\=;ZC]7DY60>:,&N\^3W>"Z6EZ-P!.9L0=>)N,LW/S$U(:^T-\N3HOH$ MF_K9 (_ ;%V(/%6#I0=IG-7?]$4M1&L =@T#D!J *K]KH,K+KU30Z83G&\#+ MIZ6U\J"::C5:.A=G953N!9=W8SE.3'_)!0,0@D_@?DDY^U3.< ZN\U2&O:#5 MPLE;(I\]@>^K\K0 W]>B$#2;Q]DCN/C*!(V3XL/$$=*;TJ8S4\A7-3(R(&-P MDV=B68!OV9S-=\<[^/RC:XB#-U^ '\ PY!U9[7EKW*#[A$&I=( M?Y#QCU7K/\R0I?5@Q7J_XP7G4H$%KQ;VQ M?WBU_<93W^KIM]H7^I"PHQ/ WT\ UP]@Y!YV*6A<"OJ[-$P"V %5 ECB'C:N MAWU<9^"VBNP=S:3'$/QYP]('QO^R($0-0F1%N-TFR'^RZ".06B3O\0JR?TK5 M:'XKANAP]*"KV==]HXOKU>H-+BJX=MJC<109W&R)!#P;]2G3.ZF/7,\U9#Y$ MVBGTWN37@4@4^R'/ZV(_J%4%'B$KP_&?0MW-! (-BZX%!]H%X!0.5*9[9X)6 M$&B7D#.P8 ?B,9F@Y07VTI==1D1]&!%JO8!V_AZ:$Q5[&/S2\>B.M/\BN!J=0H3+=-_Y:3)!=3,[ A!V(/>*OQ07U$I== L1]"!!I MK4!VYAZ: !5,<#&A'#-6[0("[7@60UA9TA+8,R(31@43P#"^%6*L.MFO *4RH M3+<3P0_=*# 4$=9B@NUB<@8J[$#<;HY@%'9E M8J@WNIS"XGDCZ6@M8;?(3>#$>*"K6=">'815'[SQ !K4JXUV;7VQ@R MW']7C$($#;N96(L,MHO,.1C2CNCW_]E,M/J07NJSRY!>'X8D6DR(G=J'9D@% MUV9(:'CY)UHJB%TJAJ9(!;>SA12,74/>$2TWY'R-%++?20E_? M2;$CDLX?3D2K#OE?>BADOXD"_;%OV/4F6H_(^1HI9+^3XED20(L+>?=.2@;%OF7NC&L'Z_[ZS>4/\99 1*V MD$/=<2!7D-&2T3GCY0/R_B+/Q?:D!&C^<6#Z+U!+ M P04 " 'A*52L\B[4F8" !8!0 &0 'AL+W=O3;TCI'F*4UV^(*[4.]T&2%/4K!*Y2&*PD:-^-@$M],1R[>!SQR MW)NC-;A.UDH].>-[,0XB1P@%YM8A,/KM<(9".""B\:?##/J2+O%X_8+^U?=. MO:R9P9D2/WEARW'P)8 "-ZP1=JGVW[#KQQ/,E3#^"_LN-@H@;XQ559=,#"HN MVS\[=#H<)23QB82D2T@\[[:09SEGEF6I5GO0+IK0W,*WZK.)')?N4%96TRZG M/)O]4!8A3N S+%$PBP4LF+;/<*^9-*Q5[FR.EG%AX!X/MF'BG*(?>8ZPT&AX M@=+"KSNLUJA_T\Y,24.2<+F%%>H=Q9E^.PTM<7:5P[SC-VWY)2?X#>%.25L: MN)4%%J_S0^JU;SAY:7B:? AXQ_0%#.,!)%$2/ZSFGH"= MY+EJI#4DWS-;"QR\TI.C&<"LT9JT>D^#%OO*8[LQVF4CFJHH#7?O4+KL*5U^ M2&F)!IG.2V"R@#GN: #KRAW6[8%&VN")4WE5:]37&OVGUHG+,X!)U0JC-L?^ M]U08O5$ACJ[?RA >W?8*]=;/M &O?WOQ>V__;$S::?D7WKXY=!FV7!H0N*'4 MZ.*:*.AVCEO#JMK/SEI9FD2_+.GI0^T":'^C:'XZPQ7H']/L+U!+ P04 M" 'A*52O;X)2O\" ")#P #0 'AL+W-T>6QEUW%19/Z:ZWK#T'0K-:T(LV9K*DP2"%51;29JC)H M:D5)WH!3Q8/I9!('%6'"7\Q%6UU6NO%6LA4Z]:>CR;.WSWGJA_$[W[-TFOO[12GWQRK/WD[>.,'3M+S)Y">37!>@_74P9##8EY( ML4LE\JW!Q"85]>X(3_V,<+94#+P*4C&^L>8I&%:22^5I4T,C)@1+^SN'_F:"+*7*J1K#A/[6M)AS6H MP]9C&!C:%>7\&GKO>W' W15[NSJ!/17CT @:AI;&3H!_G\UR[]'.GD7KU>Q. MZD^MR4;T<^@5>J5HP;I^WA5C?(P]Q-E)7?/-1\Y*45&;^Y,#+N9DZ^>MI6+W M)AITRLH8J/*].ZHT6^U;?BI2W]!.;[NI*W#-TW]0\Y^M5&,!^+N1' L#B8 M LS'>F%Q_J=\9F@^%L.TS9S(#/69H3[6RX5D_0>+X_9)S.7.-$FB*(ZQBF:9 M4T&&U2V.X>MFP[2!!Q8'(OU>K?'=QCOD\3[ ]O2Q#L$RQ3L1RQ2O-2#NNH%' MDKAW&XL#'M@N8+T#\=UQH*?=/=H'"/5B>'CWA_L M*8FB)'$C@+D51!&&P-.((Y@"T( A4=2?@T?G4; ]IX+=C^_%+U!+ P04 M" 'A*52EXJ[', 3 @ "P %]R96QS+RYR96QSG9*Y;L,P#$!_Q="> M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C] M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA< MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X M4$L#!!0 ( >$I5(*8/:,Y0, &4? / >&PO=V]R:V)O;VLN>&UL MQ9E;;YLP%(#_BL7+]M(E&))>U$Q:VUTJ=5W4='N='' :JV!GMFG7_?H=&T4U M73G:"^8)L,%\''/\&7/ZJ/3]6JE[\KNNI%DD6VMW)Y.)*;:\9N:=VG$)-1NE M:V;A4-]-S$YS5IHMY[:N)G0ZG4]J)F3R_G3?UE)/P@-E>6&%DE#H"GX(_FB> MZ]TA>1!&K$4E[-,B\?L53T@MI*C%'UXNDFE"S%8]?E%:_%'2LFI5:%55BR1M M*WYP;47Q3_'*0=ZRM?$EEJUO&( LDOD4&MP(;:P_P[?/@/&!P\GM46/5)U%9 MKB^8Y9^U:G9"WKEFX"DFP6/X..RW;1!/]/^$46TVHN 7JFAJ+FT;1\TK!RC- M5NQ,0B2K^2+9GT(^R))\E!:"1"YEVQ2(H3X14*$O2P\^ M'.2YDB67AI<$]HRJ1 D<)3EC%9,%)P$D12#IB) _:0"9(9#9*) KAP.7!I Y M IF/"-F)Y R!G(T)F060(I"'PT)>PQ!.4G) SAHC)#1L#, ?,KT_<<5%EQLN)%HP5$,NSO%+7,P)KQE#.@_%"K1EI# M;GC!Q0/S%,^(F&/2@27C$>> "!.?';R+3_Z]_/BK$3MW98B)628=6#,>\]!% MLBAT R/.E6!^!O:BMS')I -;QC,> >,W""14RSMRQ9GI=#7FEW1@P7B^8Y?: M6Z;Y5E4EU^:-[VO[%$)B?DD'%DP[=D^!\AKN<*6,(4NN6^20$=-+&L4OZ3Z2 M!VO6"K&&-@WKY RFFS2&;U(O'%<-B$OF$OQ6,\ L0DQ,..G Q@GLXK+;#90N M=98PN2BZV4TQX]!1C=/Y9,"40\=3#GE[RT),]--F3.UT9N04TPX=43L0SA 3 M,P\=R3RNQ[MS#8H)B(XI(/(VQ,041$=4T(M.QRQ$Q[10-X4P"]$QOWJZF)B% MZ)C?/=W%%LQ"V9@6ZF)B%LIB6*@7,US+R# +93$LU"-+* PQT26V&!;JE64G MFIB%LA@6ZI/E03A#RC +93$L]*HL+^!-%2$F9J$LAH5>PW1)99L0$[-0%L-" M?4[O#DB8A;(8%NJ=>AR$F)B%LA@6ZIMZ=%(HQRR4Q[!0'V:GTW/,0GD,"_7. MD,)Q,\P4"]FN*:>8Q;*8UBH%W,68J*_>F)8J!=S'F)B%LIC6*AO<::; M0IB%9\YI9Z-DU5G4/9-WFE6+G_ M2[S_P_W^+U!+ P04 " 'A*52_2S5I:X! #!&P &@ 'AL+U]R96QS M+W=OE0G^/^T,3>Y52=X[S8I]1\ M.!?7^W J8[]NPOEV95NWIS+=ENW.->7Z6.Z"T\%@Y-K7&<5B]CJSM[HVX3\3 MZ^WVL Z?]?K[%,[IC\'NIVZ/<1]"*GJKLMV%-"_CNY^D/YMBOJK01Z*^JM!'HKZJT$>BOJ MK01Z*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>EMGLX1 ;T.]C4!O0[V-0&]# MO8U ;T.]C4!O0[V-0&]#O8U ;X]Z>P*]/>KM"?3VJ+GD!OCWK[=^H=T[4*\=GS6./SWTEUNMT;GH^_+Q\G.^_X'6<'?^P6OU!+ M P04 " 'A*52)OJ'I[4! #<&P $P %M#;VYT96YT7U1Y<&5S72YX M;6S-F60U_ 338D(HDMVU!X^SKA1VI%HR(J M=2ZQ$N_.C+W2=\GT;6?(#;9UU;A95'AO'AAS:4&U-Z&SZ[4S2RR5+EH\+@O;+UFD3*F M*E/EPS[;--DWE]'!(0Z=78TK2N.&H2!B9QW:G9\-#GVO&[*VS&BP4-:_J#I4 ML6W%G-]5Y.)^B3,9=9Z7*64Z7=>A)7;&DLI<0>3K*MZ+#ON=?;AAVC_YU?Z= M3)]AJ%Q8;5R8F*7+[8XC:;M')@B1]67_$4^.0?KJ\U$[[8RR7WJ'Z_W0=M7- MP[%NN?Z.O\[XI']A#@&20X+D2$!RW(#DF(#DN 7)<0>2XQXD!Q^C!$$A*D=! M*D=A*D>!*D>A*D?!*D?A*D$I5('04UB@0 +$ 0 " 0 !D;V-0&UL4$L! A0#% @ !X2E4GA1.ICN *P( !$ M ( !KP &1O8U!R;W!S+V-O&UL4$L! A0#% @ !X2E4IE_5_118$ #P & @($-" M>&PO=V]R:W-H965T&UL4$L! A0#% @ !X2E4G-B#V1D M!0 1!4 !@ ("!60P 'AL+W=O$I5*'74?(H@( &D' 8 " M@?,1 !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0#% @ !X2E4BW?PO<8!0 VA@ !@ M ("!4!D 'AL+W=O$I5(*6W_.,0( (0$ 8 " @9X> !X;"]W;W)K&PO=V]R:W-H965T&UL4$L! A0# M% @ !X2E4B! 3'G' @ S@4 !@ ("!RB8 'AL+W=O M$I5*PP6_EM@, /,' M 8 " @<&PO=V]R:W-H965T$I5*QI]Z. M'@0 +\) 9 " @&UL4$L! A0#% @ !X2E4DP/\&63 @ AP4 !D M ("!(3D 'AL+W=O1&)$" "8!0 &0 @('K.P >&PO=V]R:W-H965T M$I5*G+X7!IP( ,X% 9 M " @;,^ !X;"]W;W)K&UL4$L! A0# M% @ !X2E4L6G'6_/ @ *P8 !D ("!D4$ 'AL+W=O M&PO=V]R:W-H965T$I5*1Z%C(5P0 /D) 9 " @6!( M !X;"]W;W)K&UL4$L! A0#% @ !X2E4B5! M\44L!@ U T !D ("![DP 'AL+W=O&PO=V]R:W-H965T$I5(,7\/.20< &43 9 " @&UL4$L! A0#% @ !X2E4@"]\"S+ @ C@8 !D M ("!0%T 'AL+W=O&PO M=V]R:W-H965T$I5)U44@6: ( M "\% 9 " @>MB !X;"]W;W)K&UL4$L! A0#% @ !X2E4C)P53%T @ 8@4 !D ("! MBF4 'AL+W=O&PO=V]R:W-H965T$I5(+-?MCLP( )8% 9 M " @;]J !X;"]W;W)K&UL4$L! A0#% M @ !X2E4E 5O'(: P / < !D ("!J6T 'AL+W=OV2H$ E"@ M&0 @('Z< >&PO=V]R:W-H965T$I5(PY"[R=@, /X) 9 " @5MU !X M;"]W;W)K&UL4$L! A0#% @ !X2E4L47!#Y& M @ *04 !D ("!"'D 'AL+W=OP >&PO=V]R:W-H965T$ MI5+838$1'P0 &P8 9 " @&UL4$L! A0#% @ !X2E4J4 &[-. @ @8 !D M ("!)(( 'AL+W=OSY4" "=!P &0 @(&IA >&PO=V]R M:W-H965T$I5*'U\,==P( ,L& M 9 " @76' !X;"]W;W)K&UL M4$L! A0#% @ !X2E4JP_*'8E @ %04 !D ("!(XH M 'AL+W=O&PO=V]R:W-H965T$I5*RCGZ]3P, $\* 9 M " @?.. !X;"]W;W)K&UL4$L! A0#% @ M!X2E4ASK2XR; @ MP< !D ("!>9( 'AL+W=O&PO=V]R:W-H965T$I5+U!&UL4$L! A0#% @ !X2E4F]$^3?Z P M!!( !D ("!.IL 'AL+W=O&PO=V]R:W-H965T$I5(U M-&UL4$L! A0#% @ !X2E4C1%WI1-!0 1" !D M ("!-Z8 'AL+W=O&PO=V]R:W-H M965T$I5*]O@E*_P( (D/ - M " 5BN !X;"]S='EL97,N>&UL4$L! A0#% @ !X2E M4I>*NQS $P( L ( !@K$ %]R96QS+RYR96QS4$L! M A0#% @ !X2E4@I@]HSE P 91\ \ ( !:[( 'AL M+W=O$I5+]+-6EK@$ ,$; : M " 7VV !X;"]?$I5(F^H>GM0$ -P; 3 " 6.X !;0V]N E=&5N=%]4>7!E&UL4$L%!@ V #8 L0X $FZ $! end XML 60 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 62 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 112 247 1 false 41 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.diamedica.com/20210331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.diamedica.com/20210331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.diamedica.com/20210331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.diamedica.com/20210331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Sheet http://www.diamedica.com/20210331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited Condensed Consolidated Statements of Shareholders' Equity (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) Sheet http://www.diamedica.com/20210331/role/statement-condensed-consolidated-statements-of-shareholders-equity-unaudited-parentheticals Condensed Consolidated Statements of Shareholders' Equity (Unaudited) (Parentheticals) Statements 6 false false R7.htm 006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.diamedica.com/20210331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 7 false false R8.htm 007 - Disclosure - Note 1 - Business Sheet http://www.diamedica.com/20210331/role/statement-note-1-business Note 1 - Business Notes 8 false false R9.htm 008 - Disclosure - Note 2 - Risks and Uncertainties Sheet http://www.diamedica.com/20210331/role/statement-note-2-risks-and-uncertainties Note 2 - Risks and Uncertainties Notes 9 false false R10.htm 009 - Disclosure - Note 3 - Summary of Significant Accounting Policies Sheet http://www.diamedica.com/20210331/role/statement-note-3-summary-of-significant-accounting-policies Note 3 - Summary of Significant Accounting Policies Notes 10 false false R11.htm 010 - Disclosure - Note 4 - Marketable Securities Sheet http://www.diamedica.com/20210331/role/statement-note-4-marketable-securities Note 4 - Marketable Securities Notes 11 false false R12.htm 011 - Disclosure - Note 5 - Amounts Receivable Sheet http://www.diamedica.com/20210331/role/statement-note-5-amounts-receivable Note 5 - Amounts Receivable Notes 12 false false R13.htm 012 - Disclosure - Note 6 - Property and Equipment Sheet http://www.diamedica.com/20210331/role/statement-note-6-property-and-equipment Note 6 - Property and Equipment Notes 13 false false R14.htm 013 - Disclosure - Note 7 - Accrued Liabilities Sheet http://www.diamedica.com/20210331/role/statement-note-7-accrued-liabilities- Note 7 - Accrued Liabilities Notes 14 false false R15.htm 014 - Disclosure - Note 8 - Operating Lease Sheet http://www.diamedica.com/20210331/role/statement-note-8-operating-lease Note 8 - Operating Lease Notes 15 false false R16.htm 015 - Disclosure - Note 9 - Shareholders' Equity Sheet http://www.diamedica.com/20210331/role/statement-note-9-shareholders-equity Note 9 - Shareholders' Equity Notes 16 false false R17.htm 016 - Disclosure - Note 10 - Net Loss Per Share Sheet http://www.diamedica.com/20210331/role/statement-note-10-net-loss-per-share Note 10 - Net Loss Per Share Notes 17 false false R18.htm 017 - Disclosure - Note 11 - Share-based Compensation Sheet http://www.diamedica.com/20210331/role/statement-note-11-sharebased-compensation Note 11 - Share-based Compensation Notes 18 false false R19.htm 018 - Disclosure - Note 12 - Related Party Transaction Sheet http://www.diamedica.com/20210331/role/statement-note-12-related-party-transaction Note 12 - Related Party Transaction Notes 19 false false R20.htm 019 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.diamedica.com/20210331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.diamedica.com/20210331/role/statement-note-3-summary-of-significant-accounting-policies 20 false false R21.htm 020 - Disclosure - Note 4 - Marketable Securities (Tables) Sheet http://www.diamedica.com/20210331/role/statement-note-4-marketable-securities-tables Note 4 - Marketable Securities (Tables) Tables http://www.diamedica.com/20210331/role/statement-note-4-marketable-securities 21 false false R22.htm 021 - Disclosure - Note 5 - Amounts Receivable (Tables) Sheet http://www.diamedica.com/20210331/role/statement-note-5-amounts-receivable-tables Note 5 - Amounts Receivable (Tables) Tables http://www.diamedica.com/20210331/role/statement-note-5-amounts-receivable 22 false false R23.htm 022 - Disclosure - Note 6 - Property and Equipment (Tables) Sheet http://www.diamedica.com/20210331/role/statement-note-6-property-and-equipment-tables Note 6 - Property and Equipment (Tables) Tables http://www.diamedica.com/20210331/role/statement-note-6-property-and-equipment 23 false false R24.htm 023 - Disclosure - Note 7 - Accrued Liabilities (Tables) Sheet http://www.diamedica.com/20210331/role/statement-note-7-accrued-liabilities-tables Note 7 - Accrued Liabilities (Tables) Tables http://www.diamedica.com/20210331/role/statement-note-7-accrued-liabilities- 24 false false R25.htm 024 - Disclosure - Note 8 - Operating Lease (Tables) Sheet http://www.diamedica.com/20210331/role/statement-note-8-operating-lease-tables Note 8 - Operating Lease (Tables) Tables http://www.diamedica.com/20210331/role/statement-note-8-operating-lease 25 false false R26.htm 025 - Disclosure - Note 9 - Shareholders' Equity (Tables) Sheet http://www.diamedica.com/20210331/role/statement-note-9-shareholders-equity-tables Note 9 - Shareholders' Equity (Tables) Tables http://www.diamedica.com/20210331/role/statement-note-9-shareholders-equity 26 false false R27.htm 026 - Disclosure - Note 10 - Net Loss Per Share (Tables) Sheet http://www.diamedica.com/20210331/role/statement-note-10-net-loss-per-share-tables Note 10 - Net Loss Per Share (Tables) Tables http://www.diamedica.com/20210331/role/statement-note-10-net-loss-per-share 27 false false R28.htm 027 - Disclosure - Note 11 - Share-based Compensation (Tables) Sheet http://www.diamedica.com/20210331/role/statement-note-11-sharebased-compensation-tables Note 11 - Share-based Compensation (Tables) Tables http://www.diamedica.com/20210331/role/statement-note-11-sharebased-compensation 28 false false R29.htm 028 - Disclosure - Note 2 - Risks and Uncertainties (Details Textual) Sheet http://www.diamedica.com/20210331/role/statement-note-2-risks-and-uncertainties-details-textual Note 2 - Risks and Uncertainties (Details Textual) Details http://www.diamedica.com/20210331/role/statement-note-2-risks-and-uncertainties 29 false false R30.htm 029 - Disclosure - Note 3 - Summary of Significant Accounting Policies (Details Textual) Sheet http://www.diamedica.com/20210331/role/statement-note-3-summary-of-significant-accounting-policies-details-textual Note 3 - Summary of Significant Accounting Policies (Details Textual) Details 30 false false R31.htm 030 - Disclosure - Note 4 - Marketable Securities (Details Textual) Sheet http://www.diamedica.com/20210331/role/statement-note-4-marketable-securities-details-textual Note 4 - Marketable Securities (Details Textual) Details http://www.diamedica.com/20210331/role/statement-note-4-marketable-securities-tables 31 false false R32.htm 031 - Disclosure - Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-4-marketable-securities-fair-value-of-marketable-securities-details Note 4 - Marketable Securities - Fair Value of Marketable Securities (Details) Details 32 false false R33.htm 032 - Disclosure - Note 5 - Amounts Receivable - Amounts Receivable (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-5-amounts-receivable-amounts-receivable-details Note 5 - Amounts Receivable - Amounts Receivable (Details) Details 33 false false R34.htm 033 - Disclosure - Note 6 - Property and Equipment - Property and Equipment (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-6-property-and-equipment-property-and-equipment-details Note 6 - Property and Equipment - Property and Equipment (Details) Details 34 false false R35.htm 034 - Disclosure - Note 7 - Accrued Liabilities - Accrued Liabilities (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-7-accrued-liabilities-accrued-liabilities-details Note 7 - Accrued Liabilities - Accrued Liabilities (Details) Details 35 false false R36.htm 035 - Disclosure - Note 8 - Operating Lease (Details Textual) Sheet http://www.diamedica.com/20210331/role/statement-note-8-operating-lease-details-textual Note 8 - Operating Lease (Details Textual) Details http://www.diamedica.com/20210331/role/statement-note-8-operating-lease-tables 36 false false R37.htm 036 - Disclosure - Note 8 - Operating Lease - Maturity of Operating Lease Liability (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-8-operating-lease-maturity-of-operating-lease-liability-details Note 8 - Operating Lease - Maturity of Operating Lease Liability (Details) Details 37 false false R38.htm 037 - Disclosure - Note 9 - Shareholders' Equity (Details Textual) Sheet http://www.diamedica.com/20210331/role/statement-note-9-shareholders-equity-details-textual Note 9 - Shareholders' Equity (Details Textual) Details http://www.diamedica.com/20210331/role/statement-note-9-shareholders-equity-tables 38 false false R39.htm 038 - Disclosure - Note 9 - Shareholders' Equity - Shares Reserved (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-9-shareholders-equity-shares-reserved-details Note 9 - Shareholders' Equity - Shares Reserved (Details) Details 39 false false R40.htm 039 - Disclosure - Note 10 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-10-net-loss-per-share-summary-of-significant-accounting-policies-net-loss-per-common-share-details Note 10 - Net Loss Per Share - Summary of Significant Accounting Policies - Net Loss Per Common Share (Details) Details 40 false false R41.htm 040 - Disclosure - Note 10 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-10-net-loss-per-share-schedule-of-antidilutive-shares-excluded-from-computation-of-net-loss-per-share-details Note 10 - Net Loss Per Share - Schedule of Antidilutive Shares Excluded from Computation of Net Loss Per Share (Details) Details 41 false false R42.htm 041 - Disclosure - Note 11 - Share-based Compensation (Details Textual) Sheet http://www.diamedica.com/20210331/role/statement-note-11-sharebased-compensation-details-textual Note 11 - Share-based Compensation (Details Textual) Details http://www.diamedica.com/20210331/role/statement-note-11-sharebased-compensation-tables 42 false false R43.htm 042 - Disclosure - Note 11 - Share-based Compensation - Share-based Compensation Expense (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-11-sharebased-compensation-sharebased-compensation-expense-details Note 11 - Share-based Compensation - Share-based Compensation Expense (Details) Details 43 false false R44.htm 043 - Disclosure - Note 11 - Share-based Compensation - Stock Option Activity (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-11-sharebased-compensation-stock-option-activity-details Note 11 - Share-based Compensation - Stock Option Activity (Details) Details 44 false false R45.htm 044 - Disclosure - Note 11 - Share-based Compensation - Stock Options Outstanding (Details) Sheet http://www.diamedica.com/20210331/role/statement-note-11-sharebased-compensation-stock-options-outstanding-details Note 11 - Share-based Compensation - Stock Options Outstanding (Details) Details 45 false false R46.htm 045 - Disclosure - Note 12 - Related Party Transaction (Details Textual) Sheet http://www.diamedica.com/20210331/role/statement-note-12-related-party-transaction-details-textual Note 12 - Related Party Transaction (Details Textual) Details http://www.diamedica.com/20210331/role/statement-note-12-related-party-transaction 46 false false All Reports Book All Reports dmac-20210331.xml dmac-20210331.xsd dmac-20210331_cal.xml dmac-20210331_def.xml dmac-20210331_lab.xml dmac-20210331_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2019-01-31 true true ZIP 64 0001437749-21-010912-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-010912-xbrl.zip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end